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INTRODUCTION 
 
Prostatites are a puzzling set of clinical entities that have been grouped in 
National Institutes of Health (NIH) Prostatitis Classification (NIH Chronic 
Prostatitis Workshop in Bethesda, MD, 1995; Table 1). Bacterial etiology has 
been shown for two categories – acute bacterial or NIH I and chronic bacterial 
or NIH II that are caused by known urinary tract pathogens – Escherichia coli 
and other Enterobacteriaceae and enterococci. The etiology of remaining 
categories (NIH III and NIH IV) is largely unknown. Chronic Prostatitis/ 
Chronic Pelvic Pain Syndrome (CP/CPPS) or NIH III is characterized mainly 
by long-lasting pelvic pain. This category is divided into inflammatory and 
noninflammatory subtypes, also known as NIH IIIA and NIH IIIB, according to 
presence or absence of white blood cells (WBC) in prostate secretion (EPS), 
semen or postmassage urine (VB3). Asymptomatic inflammatory prostatitis or 
NIH IV is a clinical entity that is only surficially investigated – due to lack of 
symptoms this condition is usually found by chance (Korrovits, 2008). While 
leukocytospermia has been studied in the context of infertility before, the 
category of NIH IV prostatitis was created about 15 years ago (NIH Chronic 
Prostatitis workshop in Bethesda, MD, 1995).  
The problems with prostatitis of categories III and IV include inadequate 
understanding of etiology and pathogenesis, insufficient methods for diagnosing 
and subtyping patients as well as deficient treatment schemes. On one hand, 
there is a multitude of treatment options to choose, including several experi-
mental treatment modes. On the other hand, there is a longtime tradition of 
treating prostatitis patients with antibiotics although the etiology remains mostly 
unknown. To date, it is not clear whether and which of the treatment modes are 
reliable (with a probable exception of α-blockers) since the etiopathogenesis is 
unclear. Nevertheless, any kind of prostatitis (from NIH I to NIH IV) is usually 
treated with fluoroquinolones but it is unknown whether and which bacteria are 
valid fluoroquinolone targets in case of category III or IV prostatitis. 
In Estonia, prostatitis has been the subject of interdisciplinary research 
shared by Department of Microbiology in University of Tartu and Andrology 
Centre of Tartu University Hospital since 1999 with the support from Estonian 
Science Foundation (Kermes et al., 2003; Punab et al., 2003; Korrovits et al., 
2006a; 2006b; 2008). The pertinent earlier studies of our workgroup have 
shown the presence of abundant polymicrobial communities in the semen of 
NIH III and NIH IV prostatitis patients (Kermes et al., 2003; Korrovits et al., 
2006; Punab et al., 2003). However, the role of particular species belonging to 
this microbiota as possible causative agents as well as their association with 
inflammation has remained unclear. Therefore, we focused our research on two 
groups of microorganisms. First, we investigated coryneform bacteria (Coryne-
bacterium sp. and morphologically related genera) because they are overlooked 
in routine diagnostics although some studies have associated them with pros-
tatitis. In order to supplement physicians with the data relevant to antibacterial 
treatment modes, we gathered also antibacterial susceptibility data. Second, we 
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studied mycoplasmas because some of them are associated with urethritis while 
they remain undetected during routine prostatitis diagnostics. Third, we made a 
complex study where we intended to see how microbiota (especially coryne-
forms), microelements and semen parameters relate to oxidative stress (OxS) 
that accompanies inflammatory prostatitis. 
 All studies for this dissertation were carried out in the Department of Micro-
biology in University of Tartu, Department of Biochemistry in University of 
Tartu and Andrology Centre of Tartu University Hospital. 
4
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REVIEW OF LITERATURE 
 
1. Prostate gland 
 
1.1. Anatomy and histology 
 
The prostate is a muscular pyramid-shaped exocrine gland lying on pelvic mus-
culofascial floor. It is inferior to urinary bladder and surrounds the first three 
centimeters of the urethra, and is connected to the bladder neck. The part of 
urethra that passes the prostate is three centimeters long, and ejaculatory ducts 
join the urethra at that section. The prostatic urethra is distal from the bladder. 
These glands and acini are lined by columnar secretory cells. The columnar 
secretory cells are separated from the stroma by a layer of basal cells, which 
belong to basement membrane. The prostate itself is fixed to puboprostatic li-
gaments, and surrounded by prostatic capsules referred to as “true” and “false” 
capsule. Puboprostatic ligaments connect the prostate with pubic bones. A layer 
of prostatic smooth muscles is continuous with the vesical muscles and sphinc-
ter urethrae. The glandular tissue consists of numerous follicles, which open to 
elongated canals, which join to form 15–20 excretory ducts; the ducts and ca-
nals are held together by loose connective tissue, muscular stroma and exten-
sions of fibrous capsule. Canalicular and follicular epithelium is columnar, but 
the prostatic ducts have another layer of cuboid epithelium under the columnar 
one. The prostate is 4 cm wide, 3 cm high and 2 cm deep (Churchill-Living-
stone 1995). 
Different regions of the prostate have different susceptibilities to pathologies 
and the histologists can observe regional differences in the structure and stroma 
as well. These regional differences are the reason behind a classification, which 
divides prostate to peripheral, central and transition zone. For example, the tran-
sition zone is susceptible to prostatic hyperplasia, peripheral zone to prostate 
cancer. According to Churchill-Livingstone (1995), an older classification sys-
tem divides prostate into five lobes (anterior, posterior, median and two lateral 
lobes). Some researchers deny topographical lobation; others have not managed 
to agree upon topography and terminology (Churchill-Livingstone 1995; 
McNeal 1988).  
 
 
1.2. Physiology 
 
The smooth muscles of the prostate can contract like a sponge to squeeze the 
prostatic secretions from the acini via the ducts into the prostatic urethra (Carola 
et al., 1990). If the prostate would be removed, then ejaculate would be pro-
pelled into the bladder. The prostate has abundant innervation, sympathetic and 
parasympathetic. The nerves come from pelvic plexus and form a periprostatic 
plexus. Neuropeptide Y and vasointestinal polypeptide nerve fibers are loca-
lized in the subepithelial nerve tissue, smooth muscles and walls of blood ves-
sels (Churchill-Livingstone 1995). The associations between prostatitis and 
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pain-related messenger molecules may be critical, the pain-related molecules 
being substance P, calcitonin gene-related peptide (CGRP), endorphins and heat 
receptor TRPV1 (Chen et al., 2005; Zhang et al., 2007; Tang et al., 2007; 
Meyer-Siegler et Vera 2004; Shahed et Shoskes 2001; Turini et al., 2006). 
The prostatic secretion makes spermatozoa motile and helps to neutralize 
vaginal acidity. The prostatic secretion is a minor component in the urine and a 
major component (circa 20%…30%) in the ejaculate. The volume of the eja-
culate ranges from two to six milliliters (McCance et Huether 2006). The secre-
tion of healthy men’s prostate is slightly acidic (pH 6.2…6.5), in contrast to ba-
sic reaction of seminal vesicle secretion (White 1975); those combine with 
secretions of other glands into semen with normal pH range of 7.8…8.0 (Hau-
gen et Grotmol 1998). There is a shift towards basic reaction of EPS (expressed 
prostatic secretions) in case of chronic prostatitis (Wagenlehner et al., 2005).  
The molecular composition of prostate secretion is complex, and the list of 
its constituents is not limited to those discussed below. Transition metal zinc 
was known as ‘prostatic antibacterial factor’ before knowing that it was just 
zinc (Fair et Parrish 1981). Accumulation of Zn in the mitochondria of prostate 
inhibits citrate oxidation. Hence, unusually high citrate concentrations are cha-
racteristic for the prostate (Costello et Franklin 1998). Prostatic ascorbic acid is 
very important for protecting DNA from oxidative damage (Song et al. 2006). 
Ubiquitous polyamines (spermine, spermidine, and putrescine) of seminal fluid 
originate from prostate and these stress-induced molecules regulate gene ex-
pression, cell proliferation and signaling, function as reactive oxygen species 
(ROS) scavengers, chemical chaperones, contribute to acid tolerance and are 
essential to pathogen-host interactions (Rhee et al. 2007, Lynch et Nicholson 
1997, Jakobsen et al., 1989; Lynch et al. 1994). 27 non-serum proteins were 
found from prostate fluid by Lee et al. (1986). Most pertinent EPS proteins of a 
healthy man include prostatic PAP (prostatic acid phosphatase), PBP (prostate 
binding protein) and PSA (prostate-specific antigen). These proteins are, respec-
tively, an androgen-dependent cancer marker, an androgen-dependent marker of 
secretory function, and a favorite prostate cancer marker that was also the en-
zyme responsible for semen liquefaction (Lee et al., 1986; Lam et al., 1979, 
Seregni et al. 1996; Pelletier et al., 1988; Aumüller et al., 1985; Saito et al., 
2007; Lukkarinen et al., 1993). The normal prostate fluid also contains extra-
cellular messenger molecules like macrophage migration inhibitory factor and 
epidermal growth factor (Frenette et al., 2005; Fuse et al., 1992).  
Prostate is the source of small (40–600 nm) membrane-bound vesicles (simi-
lar to synaptosomes) that can fuse with sperm – these particles are prostasomes 
(Burden et al., 2006). Prostatosomes enrich spermatozoa with various proteins, 
zinc and calcium; these contribute to semen liquefaction, act against bacteria, 
influence immune system and, finally, stimulate the acrosome reaction (Steg-
mayr et Ronquist 1982, Arienti et al., 2004; Vivacqua et al., 2004, Oliw et al. 
1993; Siciliano et al., 2008). Hence, the prostatosomes seem as if supple-
menting the spermatozoa during the period, starting with spermatozoa exposing 
to prostate secretion and ending with the fertilization.  
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In the present thesis, relation between leukocytospermia and inflammation 
of the prostate is an important topic. In that context, it is crucial to know that the 
leukocytes in semen seem to come normally mainly from epididymidis while in 
case of pathology from prostate instead (Tsuboi et al., 2007; Wolff 1995; Haidl 
1990; Simbini et al., 1998). 
 
 
2. Prostatitis 
 
2.1. Concept and classification 
 
Prostatitis is an arbitrary term for a common but poorly understood concept. 
Evidence of forsaking logic and reason altogether is present as the diagnostic 
category of so-called “non-inflammatory prostatitis”. Prostatitis does have cha-
racteristic symptoms but these symptoms are far from unique in the sense of 
sensitivity and selectivity, so it is diagnosed when the patient does not fit into 
other categories. Diagnosis is made by assessing symptoms, inflammation, and 
presence of pathogens. Fortunately, the recently developed NIH-CPSI question-
naire has improved assessing the symptoms now. The symptoms assessed by 
NIH-CPSI are divided into following categories: pain or discomfort, urination 
disorders, impact of symptoms and quality of life.  
Inflammation is measured by default from semen, postmassage urine (VB3) 
or EPS and if invasive methods are justified, then prostate biopsy is chosen. The 
older prostatitis classification stands upon on the Meares-Stamey ‘four glass 
test’ and divided patients into four categories. If a pathogen was present, then 
the prostatitis was either acute or chronic bacterial prostatitis. If the pathogens 
were not present then it depended upon whether there was inflammation (chro-
nic non-bacterial prostatitis) or not (prostatodynia) (Drach et al., 1978; Meares 
et al., 1968).  
Aiming to improve the diagnosis and treatment of prostatitis, the National 
Institutes of Health (NIH) established an International Prostatitis Collaborative 
Network. This group convened two consensus conferences (1995 and 1998) to 
establish a new definition and classification of prostatitis syndromes (Krieger et 
al., 1999). As a result, a new, NIH classification emerged along with the con-
cept of CP/CPPS that stands for chronic prostatitis/chronic pelvic pain syndro-
me, which is a composite of prostatodynia and non-bacterial prostatitis from 
previous classification (NIH Chronic Prostatitis workshop in Bethesda, MD, 
1995) (Table 1). Since enactment of new classification, there is a category for 
men with inflammation without prostatitis symptoms, which is NIH IV 
prostatitis. For sake of simplicity CP/CPPS will hereunder be referred to as 
either simply ‘prostatitis’ or ‘CPPS’ – as is commonly done – so that every 
instance of simply ‘prostatitis’ or ‘CPPS’ alone refers to CP/CPPS. Twice as 
much men show up as ill if the new classification is used instead of the old one 
(due to the new category IV). In other aspects, it may be that the differences 
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between the old and the new classification are mostly semantic, as is the opinion 
of many physicians and scientists (Krieger et al., 2002) (Table 1). 
 
 
Table 1. National Institutes of Health Classification of the Prostatitis Syndromes  
 
Category  Type  Description Presentation 
I Acute bacterial 
prostatitis 
Acute infection of the 
prostate gland  
 
Acute febrile illness as-
sociated with perineal 
and suprapubic pain, 
dysuria, and obstructive 
voiding symptoms 
II Chronic bacterial 
prostatitis  
Chronic infection of the 
prostate gland  
 
Recurrent urinary tract 
infections with pain and 
voiding disturbances 
III Chronic prostati-
tis/ chronic pelvic 
pain syndrome 
Chronic genitourinary pain 
in the absence of uropatho-
genic bacteria localized to 
the prostate gland em-
ploying standard metho-
dology 
Chronic perineal, supra-
pubic, testicular, penile 
or ejaculatory pain asso-
ciated with variable dysu-
ria and obstructive and 
irritating voiding symp-
toms 
IIIA Inflammatory  
 
Significant number of 
white blood cells in ex-
pressed prostatic secretions, 
post-prostatic-massage 
urine sediment, or semen  
See category III 
 
IIIB Non-inflamma-
tory 
Insignificant number of 
white blood cells in ex-
pressed prostatic secretions, 
post-prostatic-massage 
urine sediment, or semen  
See category III 
 
IV Asymptomatic 
inflammatory 
prostatitis 
White blood cells (and/or 
bacteria) in expressed 
prostatic secretions, post-
prostatic-massage urine 
sediment, semen, or histo-
logical specimens of pros-
tate gland 
Asymptomatic 
 
 
 
 
NIH I prostatitis is an acute bacterial inflammation due to acknowledged uri-
nary tract pathogens. NIH II prostatitis is a chronic inflammation, also due to 
acknowledged urinary tract pathogens. NIH II is generally considered a recur-
rent infection. According to Naide et al. (2006) the stereotype of recurrent in-
fection does not always fit, though, so a sub-categorization of NIH II into pri-
mary and recurrent was proposed.  
5
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NIH III prostatitis is poorly understood, as there is even no agreement 
whether it is principally a prostatitis (renaming prostatodynia to non-
inflammatory prostatitis is a sign of that). As there are difficulties in 
determining objective criteria, CPPS is considered a symptom complex. The 
important clinical feature of NIH III to point out is lasting pain (>3 months). 
Other common complaints include sexual dysfunction and LUTS (lower urinary 
tract symptoms). NIH III divides into two subtypes: inflammatory NIH IIIA and 
non-inflammatory NIH IIIB. Inflammation must be confirmed by increased 
WBC count in biopsy, EPS or semen.  
NIH IV is the new addition to prostatitis classification. If there is none of the 
symptoms but there is an inflammation in any prostate-specific specimen then 
NIH IV is diagnosed. NIH IV prostatitis is usually detected incidentally, most 
commonly as a ‘by-product’ of cancer or fertility testing. The body of know-
ledge regarding NIH IV prostatitis is quite small.  
The field seems to be in a phase where improved detection and recognition 
of both inflammation and pathogens is sought. More data is necessary for 
evaluation of pertinent policies.  
 
 
2.2. Clinical features 
 
The characteristic symptoms of NIH I prostatitis are those of acute UTI (fre-
quency and dysuria) and some display those of systemic infection (malaise, 
fever, myalgia). NIH II prostatitis is a chronic, usually recurrent UTI with the 
same persisting known uropathogen. NIH I and NIH II prostatites have an in-
fectious etiology but are not nearly as prevalent as CPPS. 
The lasting pain characteristic to NIH III has been described as pelvic, 
penile, suprapubic, penile, scrotal, lower back and postejaculatory. Tenderness 
and altered heat sensitivity is found in perineum as well as other body parts. 
Hyperexcitability of neurons located in the dorsal horn of spinal cord might be 
responsible for this sensitization (Yang et al., 2003; Berger et al., 2007; 
Shoskes et al., 2008). The men with prostatitis are sensitized not only to the 
heat but also to the opposite, the cold, as well (Hedelin et Jonsson, 2007). There 
is a link between premature ejaculation and CPPS, especially in case of the in-
flammatory form (Trinchieri et al. 2007; Shamloul et al., 2006). Lower urinary 
tract symptoms (LUTS – frequency, urgency, nocturia) may also be a concern in 
case of CPPS, to the extent that it becomes similar with painful bladder 
syndrome / interstitial cystitis (Hedelin et Jonsson, 2007). The prostate of a 
CPPS patient may be normal, tender or boggy; usually the prostate is not en-
larged like in case of benign prostatic hyperplasia (Roberts et al., 1999). 
The men with prostatitis have troubles with mood, personality and sexuality 
(Anderson et al., 2008; Mehik et al., 2001; McNaughton-Collins et al., 2001; 
Keltikangas-Järvinen et al., 1981 and 1982). The sexual problems are loss of 
libido, erectile dysfunction and decreased sexual activity. Psychical disorders 
include anxiety, depression, paranoia, compulsions, affect lability, weak 
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masculine identity and features suggesting of borderline, narcissistic and 
alexithymic personalities. Their increased stress is also reflected in heightened 
levels of awakening cortisol (Aubin et al., 2008). 
 
 
2.3.  Histopathological aspects 
 
The diagnosis of NIH IIIA or NIH IV prostatitis is based on heightened amount 
of leukocytes in semen, expressed prostatic secretions (EPS) or in the prostate 
biopsy material. Of these, obtaining prostate biopsy has the greatest prostate-
specificity but it is invasive; EPS, if obtainable, yields tiny amounts of quite 
specific material; semen is the least specific but it is the easiest to obtain, and in 
most cases, also most abundant.  
Comparison of prostatitis symptoms with histologic inflammation has re-
vealed controversial results. A prospective prostatitis study by True et al. (1999) 
revealed that only a third of CPPS patients had any histological inflammation 
(5% of them had moderate or severe glandular, periglandular or multifocal in-
flammation) while Schatteman et al., (2000) reported that almost every set of 
prostate biopsies contained inflammatory material. In some studies, leuko-
cytospermia has shown poor correlation with histological inflammation and 
hyperemia (Tsuboi et al., 2007; Cho et al., 2000). In other studies, histological 
inflammation is commonly observed; especially the perivascular inflammation 
has been associated with elevated PSA levels that indicate tissue damage 
(Gümüs et al., 2004, Hasui et al., 1994). In a study of 5597 men with and 
without prostatitis-like symptoms by Nickel et al. (2007), significant corre-
lations were found between average chronic inflammation, and total Chronic 
Prostatitis Symptom Index score and subscores for urinary symptoms and qual-
ity of life but the magnitude of these correlations was small. Histological in-
flammation is proved ubiquitous (98%) in men with BPH as well (Kohnen et 
Drach 1979). 
Some researchers have investigated whether body parts other than prostate 
might play a role in the pathogenesis. Parsons (2007) has suggested a new para-
digm of dysfunctional urothelium diseases, which would include prostatitis, 
urethritis and interstitial cystitis (or painful bladder syndrome). Urothelium 
(urinary epithelium) is a barrier between urine and other tissues. The protective 
barrier is formed of anionic mucus (glycosaminoglycans) and the disruption of 
that barrier allows migration of K+ into interstitial space that depolarizes nerves 
and muscles, and cause tissue injury. Traditionally this potassium sensitivity is 
associated with the diagnostic window of painful bladder syndrome (also 
IC/CPPS – interstitial cystitis / chronic pelvic pain syndrome) but this potas-
sium sensitivity is observed in prostatitis diagnostic window as well (Hassan et 
al.; 2007, Parsons 2007). Correlation between severe LUTS and positive K+ 
sensitivity test in prostatitis patients show that urothelium is impaired (Hassan 
et al., 2007).  
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Finally, there is emerging evidence that inflammation of the prostate may 
contribute to either hyper- or neoplastic changes, thus leading to BPH or pros-
tate cancer, respectively (Sciarra et al., 2008). 
 
 
2.4. Defense mechanisms of a human 
 
When the defense mechanisms of humans are considered, then it must be taken 
into account that the pathogenesis mechanisms of prostatitis are unclear, al-
though the later research has granted some more insight. Finer defense mechan-
isms of the man against CP/CPPS are related to the theories of etiology and 
pathogenesis. Three main theories (autoimmune, infectious and neuromuscular) 
point out their respective causes of CP/CPPS: (1) the immune system’s liability 
to develop autoimmune disease; (2) infectious agents; (3) sensitization towards 
neuromuscular pain. 
     Well-known defense factors related to male lower genitourinary tract of 
macro-organism include the presence of T-cells and tissue macrophages in nor-
mal prostate and the capability to recruit other immune cells. One possible 
mechanism for prostate to recruit macrophages, neutrophils and mast cells is 
that they are summoned by chemokine IL-15 (Handisurya et al., 2001, 
Brzezińska-Błaszczyk et Misiak-Tłoczek 2007). IL-15 is only one element of an 
immunologic cascade that includes IL-18, leukotrienes, TNFR-1, MIP-1α 
(CCL3), MIP-2, 5-LOX, TNF-α, and TLR4, while IFN-γ is not part of that 
particular cascade (Verri et al., 2007).  
 Prostate secretes antibacterial zinc-containing proteins. In healthy men, the 
average concentration of zinc in EPS was 448 µg/ml; in prostatitis patiens it was 
50 µg/ml (Fair et al., 1976). The antibacterial activity of Zn was shown in a 
straightforward study by Cho et al. (2002) where the Zn2+ solution was injected 
directly into the prostates of the rats. The distribution of Zn2+ is influenced by 
stress, adrenergic signals or glucocorticoids in one way (intracellular Zn2+?), 
and by cholinergic signal in another (intracellular Zn2+?) (Berehova et al., 
2007). Anti-infectious properties have also been attributed to Surfactant Protein 
D, which protects epithelial cells against Chlamydia trachomatis and is upre-
gulated during prostatitis (Oberley et al., 2005).  
 Normal flow of the urine, its acidity, high osmolarity and antibacterial fac-
tors, longer urethra in males, intact urothelium and secretion of IgA to mucosal 
surfaces have protect against infections as well. 
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2.5. Epidemiology 
 
2.5.1. Types of studies 
 
Epidemiology of prostatitis has been researched using questionnaires in the 
following types of studies: cross-sectional study (Ejike et Ezeanyika 2008), cohort 
study (Shoskes et al. 2008), and case-control study (Bartoletti et al., 2007). The 
methods of delivering questions includes direct delivery (Ejike et Ezeanyika, 
2008), regular mail (Mehik et al. 2000), recruiting urologists randomly (Nickel et 
al. 2005) and by using the Internet (Mazzoli et al. 2007). In addition, database 
research is a mean for epidemiological study (Clemens et al., 2007). There are 
also epidemiological studies on prostatitis which are based on cooperation of 
multiple hospitals or research facilities (multi-centre studies); these are made in 
order to improve objectivity and remove bias (Rizzo et al., 2003). The benefits of 
getting answers from people by mail rather than telephone are wider range of 
responses and minimized ‘acquiescence biases, according to Hall (1995).  
Several questionnaires have been used in order to assess symptoms of prosta-
titis (Schneider et al., 2003): Giessen Prostatitis Symptom Score (GPSS), Inter-
national Prostate Symptom Score (IPSS), Chronic Prostatitis Symptom Index of 
the National Institutes of Health (NIH-CPSI). The latter is a valuable tool for both 
clinical and epidemiological studies. Since questionnaires measure symptoms, 
laboratory tests must be used to find out the prevalence of NIH IV prostatitis. 
 
 
2.5.2. Prevalence of prostatitis 
 
The prevalence of CPPS (NIH IIIA and NIH IIIB combined) has ranged from 
2,7% to 14,2% (Table 2). The incidence of CPPS is 33…37 per 10 000 person 
years while the prevalence of ejaculatory pain (a most characteristic specific 
symptom of CPPS) is from 1 to 9% in general population (58% in NIH IIIA or 
NIH II patients) (Mehik et al., 2000; Ilie et al., 2007; Clemens et al., 2005). 
 
 
Table 2. Prevalence studies of prostatitis 
 
Prevalence Study population Reference 
14,2%, 
1832 men from Finland, 20–59 years old. 
Cross-sectional postal survey, 75% 
response rate. 
Mehik et al., 2000 
13,8% 
2006 men from 28 centers, 25–50 years 
old. Prospective case-control study of 28 
urology clinics. 
Bartoletti et al., 2007 
12,8% 8503 men from Italy, 16–83 years old. Cross-sectional study by 70 urologists. Rizzo et al., 2003 
12,2% 1507 men from Nsukka, Nigeria, 20–70 years old. Random cross-sectional survey.
Ejike et Ezeanyika, 
2008 
6
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Prevalence Study population Reference 
9,7% (11,5% in 
the younger, 
8,5% in the older 
subgroup) 
868 men divided into subgroups of 
younger and older men, 20–50 and 51–74 
years old, respectively. Cross-sectional 
postal survey. 
Nickel et al., 2001 
4,5% 
Computer database research in USA. 
Prostatitis-patients were compared with 
age-matched controls. 
Clemens et al., 2007 
2,7% 1765 men, 20–79 years old Marszalek et al., 2007 
2,7% 
6037 men, comparative prevalence study 
of prostatitis, interstitial cystitis and epi-
didymitis. The patients were seen by ran-
domly recruited urologists. Urology out-
patient study. 
Nickel et al., 2005 
 
 
2.5.3.  Risk factors of prostatitis 
 
The researchers have found many epidemiological correlates for CP/CPPS 
(Table 3). For example, Pontari et al. (2005) estimated the risk factors and 
found that CP/CPPS patients had five times higher prevalence of cardiovascular 
disorders, triple prevalence of urethritis or neurological disease, two and half 
times greater prevalence of psychiatric conditions, double prevalence of haema-
topoietic, lymphatic or infectious diseases. It seems that bicycling is often as-
sumed as a risk factor of prostatitis. There are some case reports of pudendal 
nerve injury along with otherwise interesting theory of pudendal nerve entrap-
ment. Dangers of bicycling are reviewed by Asplund et al. (2007) and they 
stated that majority of bicycling injuries are due to overuse, improper equip-
ment, technique, or training patterns. In addition, many papers provide casuistic 
evidence or mention the dangerous side of bicycling  (Leibovitch et Mor 2005, 
De Rose et al., 2001; Antolak et al. 2002, Ramsden et al., 2003). 
 
 
Table 3. Epidemiological correlates of CP/CPPS 
 
Risk Factor Reference 
Cigarette smoking Bartoletti et al, 2007 
High-calorie diet with low intake of fruits and vege-
tables Bartoletti et al., 2007 
Sexual relationship with more than one partner Bartoletti et al., 2007 
Coitus interruptus Bartoletti et al., 2007 
Frequent masturbation Gao et al., 2007 
Long-time urine holding Gao et al., 2007 
Sitting or driving Gao et al., 2007; Chiappino et Pisani, 2003 ; 
Constipation Bartoletti et al., 2007 
Meteorism Bartoletti et al., 2007 
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Risk Factor Reference 
Slow digestion Bartoletti et al., 2007 
Dyspepsia Clemens et al., 2007 
History of UTI-s 
Gao et al., 2007 ; Daniels et 
al., 2007 ; Pontari et al. 
2005 
Cold environment and stress Gao et al., 2007; Mehik et al., 2000 
Cardiovascular diseases Pontari et al. 2005; Collins et al., 2002 
Neurological disease Pontari et al. 2005; 
Psychiatric conditions (mood, anxiety, other) 
Pontari et al. 2005;, Cle-
mens et al., 2007; Collins et 
al., 2002 
Hematopoietic, lymphatic, infectious disease Pontari et al. 2005; 
Esophageal reflux Clemens et al., 2007 
Being widowed Mehik et al., 2000 
Similar diseases (BPH) Clemens et al., 2007; Col-lins et al., 2002 
History of STD-s Collins et al., 2002 
 
 
2.5.4. Similar and comorbid diseases 
 
Prostatitis shares a lot of similarity with other symptom complexes, especially 
with benign prostate hyperplasia (BPH) and painful bladder syndrome (PBS, 
also known as IC – interstitial cystitis). According to Barry et al. (2008), the 
population fitting into diagnostic window of NIH III shares almost half of its 
men with the diagnostic window of BPH. There is smaller but still remarkable 
overlap with the diagnostic windows of incontinence and that of IC or painful 
bladder syndrome (PBS).  
CPPS is distinguished from BPH by pain, while the urinary symptoms may 
be similar. Especially the pain on ejaculation indicates prostatitis but not BPH. 
According to Nickel et al. (2005), about 20% of BPH patients have pain or dis-
comfort on ejaculation. These BPH patients having prostatitis-like symptoms 
did clearly differ from the patients with just LUTS, because their LUTS were 
severe, they had higher prevalence of erectile dysfunction, and reduced ejacu-
lation. Of immunological markers, elevated concentration of IL-8 in the semen 
is common in both BPH and NIH IIIA prostatitis (Penna et al., 2007). The 
treatment of BPH and prostatitis is overlapping as concerns α1- or α1A-adre-
noblockers (Nickel 2008; Lee et al., 2007; Nickel et al., 2003; Dunn et al., 
2002; Duclos et al., 2007).  
Similarities between prostatitis and PBS (IC) include but are not limited to 
etiology or pathophysiology, treatment and positive K+ sensitivity test and im-
pact on quality of life (Hassan et al., 2007; Pontari 2006; Peters et al., 1999, 
Barry et al., 2007). IC patients have 40 times higher risk of also having (or “fit-
ting into category of”) chronic prostatitis (Wu et al., 2006). Urinary cytokine 
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profile of IC has been provided by pioneering work of Peters et al., (1999), rise 
of IL-2, IL-6 and IL-8 is a trait common with prostatitis. Further similarities 
between the symptom complexes cannot be assumed, because Khadra et al. 
(2006) investigated IL-8 from both urine and semen of CPPS patients and found 
IL-8? solely from semen, not urine. There is currently not enough information 
for a valid comparison between the cytokine profiles of IC and prostatitis.  
In addition to similar diseases like BPH, IC and occasional pudendal nerve 
entrapment, there are other diseases reported as comorbid with prostatitis (Table 
3). These diseases are allergies, anxiety disorders, depression, erectile dys-
function, ejaculatory dysfunction, gastrointestinal disorders, premature ejacu-
lation, irritable bowel syndrome, rheumatologic diseases, sinusitis, psychiatric 
conditions and various soft tissue disorders (Antolak et al. 2002; Clemens et al. 
2006; Clemens et al.2007; Wu et al. 2006; Trinchieri et al. 2007; Li et al., 
2002; Naughton-Collins et al. 2001; Pontari 2003). 
 
 
2.6. Impact on life quality 
 
Prostatitis seriously affects the quality of life (Wenninger et al,. 1996; Walz et 
al., 2007; Smith et al., 2006). In a study of Walz et al. (2007), 10.5% of men 
had prostatitis-like symptoms, which adversely affected the quality of life in 
growing order of magnitude: urinary frequency, incomplete bladder emptying, 
pain frequency and pain intensity. According to Tripp et al. (2004), the main 
predictors of prostatitis patient’s life quality were LUTS, depressive symptoms 
and pain intensity. The negative impact of prostatitis is comparable to that of 
myocardial infarct or Crohn’s disease. Prostatitis is a problem not only to the 
patient but to his female partner, too. 
 
 
2.7. History of prostatitis research 
 
The pioneers of prostate research were Herophilus (circa 350 BC) and Nicola 
Massa (16th century) who elucidated prostate anatomy. Legneau described 
prostatitis syndrome in 1815. In the last two decades of 19th and in the three 
first decades of 20th century the bacteria were sought as etiological factor. Later 
on, the possibility of other etiological factors was taken more seriously, while 
some doctors and psychoanalysts denied the existence of chronic prostatitis at 
all (summarized by Mehik, 2001). The invention of four glass test (Meares et 
Stamey, 1968) and prostatitis classification (Drach 1978) fueled the following 
prostatitis research.  
The last decade of 20th century saw the acceleration of prostatitis research, 
including increase in therapeutical options and a new prostatitis classification. 
To improve the diagnosis and treatment of prostatitis, the National Institutes of 
Health (NIH) established an International Prostatitis Collaborative Network. 
This group convened 2 consensus conferences (1995 and 1998) to establish a 
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new definition and classification of prostatitis syndromes (Krieger et al., 1999) 
(Table 1). It was speculated that a new era of prostatitis research begins, be-
cause of new classification, validated symptom assessment tool (NIH-CPSI) 
and consensus on the future of prostatitis research (Nickel 2000). The beginning 
of 21st century saw also a critical revision of extant treatment modes, ‘prostato-
centric approach’ and infectious etiology (Potts et al., 2003). The rising activity 
in the field is evident: 2301 articles are available in PubMed in answer to a 
query of “chronic prostatitis” and 1090 of these have been published in the 21st 
century. Research involves continued search for pathogens, elucidating im-
mune, neural and oxidative mechanisms behind prostatitis. In addition, several 
animal models have been developed, new epidemiologic surveys have been 
made and from the practical side there is an ongoing search for better diagnostic 
and treatment options. Incremental additions to mainstream theories are made 
steadily, and even the possibility of paradigm shift for the entire field has been 
discussed, and that is good, because the fundamental question why these pa-
tients suffer is still unanswered. 
 
 
2.8. Theories of etiology and pathogenesis 
 
Infectious, autoimmune and neuromuscular – these have been the main theories 
of etiology during last two decades. Additional etiopathogenesis theories in-
clude but are not limited to anatomic and traumatic (Vega 2000; Nickel 2002), 
prostatic stones (Geramoutsos et al., 2004), hormonal (Dimitrakov et al., 2008), 
urothelial dysfunction (Parsons, 2007), and most recently, dysbacteriosis (Liu et 
al., 2009). Theory of multifactorial cascade (Nickel, 2002) has attempted to tie 
some more specific mechanisms into a related complex form. 
 
 
2.8.1. Theory of multifactorial cascade 
 
Nickel (2002) has postulated that the pathogenesis of prostatitis may involve 
several inter-related pathogenetic pathways, starting in an initiating event and 
culminating in a neuropathic state (Fig. 1). These ‘initiators’ can be infection, 
high pressure dysfunctional voiding, trauma or toxin. This initiating event can 
result in either injury and/or inflammation. The injury could be to the local 
nerves and muscles or even the prostatic glandular or stromal tissue. Inflam-
mation likely is initially restricted to the prostate and peri-prostatic area. The 
initial neuropathy or immunologic reaction may progress because of persistent 
initiating factors (persistence of bacteria, dysfunctional voiding or perineal 
trauma). Neuropathic and immunologic pathology can persist, even with era-
dication of or amelioration of the initiating factor, through a self-perpetuating 
stimulatory loop. Inflammation can continue because of initiation of a new 
autoimmune mechanism. Inflammation in the prostatic and peri-prostatic area 
can promote a neurogenic reaction resulting in chronic neuropathy. It is also 
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recognized that peripheral neuropathy can initiate and promote a progressive 
and durable inflammatory reaction. Up-regulation of the local pelvic neural loop 
perpetuates the neuropathic state. The result for the patient is pain in the peri-
neum, pelvis and genitalia, abnormal voiding parameters and because of the 
proximity of the erectile mechanisms in the area, various degrees of sexual dys-
function. Therapies aimed at the initiating factors are important to eradicate po-
tentiating agents but, in the long term, they may be ineffective, because the 
syndrome has progressed along the spectrum of diseases, where the initiating 
event may now be irrelevant. This is the rationale for the introduction of neuro-
logic medications, neuromodulatory interventions and physical therapies. 
As concerns the neuropathic state, it might be viewed as a vicious circle, 
since neural irritation of one pelvic organ could have radiated through spinal, 
maybe also supraspinal mechanisms into other pelvic organs due to pelvic 
cross-sensitization (Malykhina, 2007; Chen et al., 2005). Data support the idea 
that neural circuits operating in a pathogenic mode unleash and keep up an cas-
cade of factors which influence not only one pelvic organ but are capable of 
dealing collateral damage to other organs as well (Meyer-Siegler et Vera, 2004; 
Vera et Meyer-Siegler 2004; Zhang et al. 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Scheme of multifactorial cascade in pathogenesis of prostatitis (Modified from 
Nickel et al., 2002). 
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2.8.2. Infectious 
 
NIH I and NIH II prostatitis are considered infectious diseases because tradi-
tional uropathogens, like E. coli or enterococci, can be isolated employing rou-
tine tests (Nickel 2002). At the same time, NIH III prostatitis (CPPS) lacks ‘tra-
ditional’ uropathogens in prostate-specific materials (semen, VB3 or EPS). 
Hence, only routine cultures do not differentiate between healthy men and 
CPPS patients. This has been expressively shown by Nickel et al. (2003), who 
found controls and CPPS patients as microbiologically similar, and it did not 
make any difference whether the chosen specimen was semen, EPS or VB3. 
Microbial counts have not been found to correlate with symptoms, either 
(Schaeffer 2003; Shoskes et al., 2004).  
Opinions about the plausibility of infectious etiology have ranged from one 
extreme to another: one group declared evidence non-existent (Potts et al., 
2003); another suggested that the major cause was a single overlooked pathogen 
(Skerk et al., 2007); third was wary of extant but encouraging about future evi-
dence (Pontari et Ruggieri, 2008). Whether Gram-positive organisms other than 
enterococci can be considered commensals or pathogens is a good question, and 
while the ‘final truth’ is not yet there, some preliminary answers have been pro-
vided by Tanner et al. (1999), Shahed et Shoskes (2000), Ivanov et al., (2008) 
and by our previous research (Kermes et al., 2003). Many groups have under-
taken the task to improve detection limits or find out unusual pathogens (Tanner 
et al., 1999; Takahashi et al., 2003; Szöke et al., 1998; Skerk et al., 2004; Budía 
et al., 2008; Villanueva-Diaz et al., 1999; Krieger et al., 1996). Hua et al., 
(2005) reviewed the topic of unusual pathogens and concluded that specific 
microorganisms (atypical pathogens) explained prostatitis in up to tenth of the 
patients.  
 
 
2.8.2.1. Microbiological studies using conventional methods 
 
In order to discern pathology one must know the norm. In case of any prostate-
specific material (EPS, semen or VB3), there is an inherent possibility of 
urethral contamination. Rehewy et al. (1979) have studied semen of healthy 
men and found Staphylococcus epidermidis, Staphylococcus aureus, Coryne-
bacterium sp, Mycoplasma hominis and Ureaplasma urealyticum. The study by 
Willen et al. (1996) was an in-depth analysis of normal urogenital microflora. 
They studied nearly one hundred healthy men scheduled for vasectomy and 
compared microorganisms from vas deferens, EPS, semen and distal urethra 
(coronal sulcus) using aerobic and anaerobic cultures. Their results showed that 
CNS and streptococci (but not corynebacteria) were the dominant microbial 
groups, and the main source of these bacteria was urethra. According to studies 
of Montagnini-Spaine et al., (2000) in healthy urethra and prostate secretions 
the predominating microorganisms were CNS, viridans streptococci, Coryne-
bacterium sp. and Enterococcus sp.  
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2.8.2.1.1. Expressed prostatic secretion 
Most of the studies have implemented expressed prostatic secretions (EPS), a 
traditional sample in prostatitis studies. Bartoletti et al. (2007) used 152 prob-
ably infertile men as controls for 2006 prostatitis patients. Their microbiological 
study implemented traditional Meares-Stamey four-glass test that was positive 
in 13,3% of prostatitis patients and 2,9% of infertility patients. In addition, 6% 
of Meares-Stamey negative prostatitis patients carried agents of sexually trans-
mitted disease in their urethras.  
Shahed et Shoskes (2000) have considered any Gram-positive aerobic bacte-
ria (mainly staphylococci, enterococci and corynebacteria) as pathogens if those 
were expressed specifically in EPS or were expressed in 100 times higher con-
centration in VB3 than in VB1. The most common Gram-positive microorga-
nisms in their study were staphylococci, enterococci and corynebacteria. If these 
Gram-positive microorganisms were present in such quantities, then the authors 
diagnosed chronic bacterial prostatitis (NIH II).  
Anaerobic bacteria have been seldom searched from prostate-specific speci-
mens. Szöke et al., (1998) searched for anaerobic species using a cut-off value 
of 106 CFU/ml and 6-day incubation. As a result, they observed that 18 of 50 
patients were positive for anaerobes only, six of 50 were positive for both aero-
bic and anaerobic species and none was positive for solely aerobic bacteria. 
Nearly half of the patients (26 men) remained microbiologically negative at this 
cut-off value. Peptostreptococcus sp. was quite usual (54%), followed by Pro-
pionibacterium sp. (30%), Bacteroides ureolyticus (20%), Prevotella sp. (16%), 
Bifidobacterium sp. (14%), Eubacterium sp. (12%), Prevotella sp. (10%) and 
Veillonella sp. (10%). Disappearance of anaerobes from EPS was associated 
with therapeutic success.  
 
2.8.2.1.2. Semen 
Semen is clinical sample that is relatively easy to obtain, especially in younger 
men, and is relatively less time-consuming for physician than EPS. It has been 
approved for prostatitis diagnostics by NIH workshop on chronic prostatitis in 
Bethesda, MD, USA, 1995 (Executive Summary, 1995). Although some inves-
tigators have found the sensitivity of microbiological semen analysis inferior to 
that of EPS (Weidner, Anderson 2008), the others have claimed just the cont-
rary results (Budia et al., 2006). Previous studies of our research group have 
supported the latter opinion indicating that from the microbiological viewpoint, 
semen is a suitable specimen differentiating well between prostatitis patients 
and controls (Kermes et al., 2003; Punab et al., 2003). In these studies, quanti-
tative cultures of microorganisms, including anaerobic and microaerophilic spe-
cies were employed, the most frequently found microorganisms being CNS, 
peptosptreptococci, corynebacteria and anaerobic Gram-negative rods. The 
main differences between prostatitis patients and controls were quantitative – 
inflammatory chronic prostatitis patients harbored significantly higher total con-
centration of bacteria as well as higher number of different species in their se-
men than controls. In the study of Kermes et al. (2003) also suitability of semen 
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as specimen was proved comparing semen with first-catch urine that reveals 
urethral microflora. The microorganisms’ concentration and number of species 
were significantly higher in patients’ semen than in patients’ urine, and these 
specimens shared only one third of species showing that most of the semen 
microorganisms originate from upper genital tract. In an interesting study, Iva-
nov et al., (2008) have investigated anti-complement activity of semen micro-
organisms. They found that microorganisms isolated from patients revealed 
greater anti-complement phenotype than those isolated from control group. 
They suggested that characterizing prostatitis microbiota should be focused 
upon functional parameters (resistance to host defense mechanisms) rather than 
upon classical taxonomy. In fact, already in 1975 Mårdh and Colleen found that 
the semen of healthy men inhibited the growth of staphylococci more than the 
semen of prostatitis patients. 
 
2.8.2.1.3. Prostate tissue 
Physicians usually do not use biopsy to diagnose prostatitis. Prostate tissue has 
mainly been researched in association with prostate cancer diagnostics, and there 
are a few studies, which have used samples from organ donors. There are three 
types of prostate biopsy: transrectal, transperineal and transurethral. Usually, the 
physicians have stuck to the transrectal approach (Ravery et al., 2000). All these 
methods may be associated with contamination of specimen, especially transrec-
tal, although double needle techniques can help to diminish it. Doble et al., (1989) 
found bacteria from only 15% of patients’ biopsy samples while Lee et al. (2003) 
found that this number would be approximately 37% in both patients and con-
trols, and both groups used transperineal biopsy, which minimized bacterial 
contamination. Doble et al. (1989) treated their patients with antibiotics respec-
tive to these bacteria. The treatment failure led the authors to the idea that these 
bacteria were contaminants rather than causative agents. The authors also took 
special effort to clarify whether chlamydiae were behind prostatitis, but they did 
not find any active chlamydiae in the prostates nor did they find moderate or 
higher serum titers of Chlamydia trachomatis antibody. Matsumoto et al., (1992) 
reported that biopsy culture is seldom positive compared with EPS or semen. 
They reasoned that the infections could have been focal ones. Berger et al. 
(1997), on the contrary, could demonstrate that inflammatory EPS correlated with 
isolation of any bacteria, including anaerobes, as well as higher bacterial counts 
and more species isolated in biopsy material. The latter is in good correlation with 
our former study (Kermes et al., 2003). 
 
 
2.8.2.2. Microbiological studies using genotypic methods 
 
Researchers have used nucleic acid probes not only for detection of individual 
species but for detection of any prokaryotic species as well. That was possible 
by using sequences that coded 16S subunit of the ribosome, which has been 
relatively resistant to changes during the course of phylogenesis.  
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2.8.2.2.1. Expressed prostatic secretion 
The EPS studies that implement genotype-based methods form a group of stu-
dies that point in the direction of infectious etiology. Tanner et al., (1999) found 
with 16S rRNA probe an unexpectedly diverse list of Corynebacterium species, 
some of them characteristic to men with prostatitis. These bacteria were often 
unculturable. Interestingly, 7 of 11 men who had bacteria in EPS were sus-
ceptible to treatment with antibiotics. Ribosomal DNA of ‘atypical pathogens’ 
(Chlamydia, Mycoplasma or Trichomonas) has been found as well – Krieger et 
al. (1996) found that 8% of CPPS patients had one of those, and Skerk et al., 
(2007) detected Chlamydia trachomatis in more than third of prostatitis patients 
(using both geno- and phenotypic methods). Liu et al. (2006) found traces of 
bacteria from EPS of all NIH II patients, 94% of NIH IIIA patients and 67% of 
NIH IIIB patients. Zhou et al. (2003) found that in 78% of patients the con-
centrations of prokaryotic DNA were a log higher in EPS than in VB1 urine, 
and patients with such bacterial signal did respond better to antibiotic treatment. 
 
2.8.2.2.2. Semen 
Microbiological studies of semen have been mostly conducted in context of in-
fertility while less in prostatitis patients. Infertility has been frequently as-
sociated with leukocytospermia – that is also the basis to diagnose asymp-
tomatic inflammatory prostatitis (NIH IV). By our best knowledge, there are 
only two studies of semen that have used metagenomic methods to detect wide 
spectrum of microorganisms (Jarvi et al., 1996; Kiessling et al., 2008). 
Jarvi et al. (1996) investigated healthy culture-negative semen donors as 
well as infertile men. They found that an equal proportion, two thirds of donors 
or infertile men had at least 104 bacteria per ml by quantitative PCR. The most 
pertinent bacteria were Prevotella sp. Other bacteria included several anaerobic 
and aerobic species like Peptostreptococcus, Veillonella, Eubacterium, Coryne-
bacterium group, Rubrivirax, Actinobacillus, Streptococcus, and Burkholderia.  
Kiessling et al., (2008) investigated the presence of rDNA of micro-
organisms in the semen of men undergone fertility evaluation or vasectomy. 
Conditions of PCR were adjusted to detect only abundant organisms (>20 000 
bacteria/mL). 65% of the men were positive. The most frequently found genera 
were Peptoniphilus, Anaerococcus, Finegoldia, Peptostreptococcus and 
Corynebacterium. Normal sperm forms were lower in the rDNA positive than 
negative subjects were. The authors concluded that abundant bacteria in semen 
are not commensals but arise from infection in the male genitourinary tract. 
In addition to the two above-described studies, some scarce papers present 
data of certain species. Badalyan et al., (2003) investigated whether chronic 
prostatitis patients had Chlamydia sp. or Ureaplasma sp. in their semen and 
found one third of the both inflammatory and non-inflammatory prostatitis pa-
tients as PCR-positive.  
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2.8.2.2.3. Prostate Tissue  
Hochreiter et al. (2000) and Xie et al. (2003) have investigated the autopsy 
material from apparently healthy men for the presence of prokaryotic nucleic 
acids. Xie et al. (2003) found that fifth of the normal and half of the inflam-
matory samples had traces of bacteria inside. Hochreiter et al. (2000) found 
traces of bacteria in association with inflammatory changes due to BPH or can-
cer, while healthy prostates were void of such traces.  
In a series of studies (Krieger et al, 1996; Riley et al., 1998, Krieger et Ri-
ley, 2004), ¾ patients’ prostates have been positive for nonspecific probes, 
while 10% of patients had at least one of the following species: Mycoplasma 
genitalium, Chlamydia trachomatis, or Trichomonas vaginalis. The patient 
group of these studies was selected, though, by being refractory to multiple 
courses of antibiotics while lacking evidence of ‘true’ or ‘atypical’ pathogens. 
At the same time the results of Takahashi et al., (2003) and Leskinen et al., 
(2003) are less supportive of infectious etiology showing that 25% or 10% of 
prostatitis patients had traces of any bacteria in their prostates, respectively. The 
former study also revealed that 10% of patients were positive for Escherichia 
coli.  
 
 
2.8.2.3. Animal studies 
 
Animal models in prostatitis research have been used for immunological, micro-
biological, pharmacological and neurological studies. Rats, dogs, non-obese 
diabetes mice, guinea pigs and baboons have been used. Motrich et al., (2008) 
observed deterioration of semen quality due to OxS in rats with experimental 
autoimmune prostatitis. Phan et al., (2008) and Quintar et al. (2006) have 
investigated prostatic infections in rats and found that when they introduced a 
pathogen (Proteus or Escherischia), then an infection occurred, and that 
infection always included an acute component. In the rat model described by 
Nickel et al., (1990 and 1991) the infection of the prostate persisted in the form 
of sparse slime-protected microcolonies in prostatic ducts and acini. They found 
that the progression of the disease had striking similarities to natural progres-
sion of the disease.  
 
 
2.8.2.4. Coryneform bacteria in case of prostatitis 
 
Coryneform bacteria are aerobic, asporogenous, not acid-fast, irregular Gram-
positive rods (Funke et al., 1997). They belong to the phylum Actinobacteria. 
Their classification has undergone dramatic changes – genus Corynebacterium 
has been defined more narrowly and many species now belong to other genera 
like Arthrobacter, Cellulomonas and Rhodococcus, instead. With a notorious 
exception of C. diphtheriae, the coryneform bacteria have been considered as 
part of the normal human flora or environmental contaminants, but were rec-
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ognized increasingly as a cause of life-threatening diseases later (Bernasconi et 
al., 2004). In addition, new coryneform species were discovered frequently. 
One of them, C. seminale (also known as C. glucuronolyticum) was discovered 
first from prostatitis patients (Riegel et al., 1995).  
As mentioned before, coryneform bacteria have been frequently found in 
male urogenital tract (Rehewy et al., 1979; Willen et al., 1996; Montagnini-
Spaine et al., 2000) and some authors have associated these microorganisms 
with prostatitis (Drach, 1974; Domingue et Hellstrom, 1998; Tanner et al., 
1999, Kermes et al., 2003). At the same time, these bacteria tend to be often 
overlooked, and the unculturable or fastidious coryneforms remain undetected 
during routine culturing measures. Upgrading from blood agar to enriched me-
dia and paying extra attention to microscopy has revealed the presence of those 
Gram-positive irregular rods.  
The list of coryneforms found from healthy or prostatitis-associated male 
urogenital tract includes C. seminale (Riegel et al., 1995), C. afermentans, C. 
xerosis and Corynebacterium group ANF (Tanner et al., 1999), C. singulare 
(Riegel et al., 1997), C. freneyi (Renaud et al., 2001), C. striatum or C. amyco-
latum, C. macginley, C. jeikeium, Dermabacter hominis (Jedrzejczak et al., 
2005), C. minutissimum (Domingue et al., 1997) and even the notorious C. 
diphtheriae (Machado et al., 1989). In addition, Gardnerella vaginalis (a cata-
lase-negative, bacterial vaginosis-associated coryneform) has been found from 
male genital tract (Hillier et al. 1990).  
Nucleotide-based studies by Tanner et al. (1999) and Lee et al. (2007) both 
showed that Corynebacterium sp. were the most common bacteria in the EPS or 
urine, respectively, among prostatitis patients. More specifically, Coryne-
bacterium species were more prevalent, abundant and represented by higher 
number of species in prostatitis patients than controls. Tanner et al., (1999) even 
found some yet unidentified species that were restricted exclusively to the pa-
tients. This study showed the limitations of classic microbiology as PCR ma-
naged to detect nine species from one patient alone. It has been also speculated 
(but not proved) that coryneforms could grow in the prostate as a biofilm that 
would enhance antibiotic resistance (Tanner et al., 1999).  
Since coryneform bacteria may be associated with prostatitis, it may be valu-
able to know about their susceptibility. Domingue and Hellstrom (1998) and 
Funke et al., (1996) have investigated and reviewed the huge differences in the 
antibiotic susceptibility patterns of coryneform species. The resistance profiles 
of corynebacteria have been species-specific but not without their peculiarities. 
For example, a generally multiresistant species (C. amycolatum) was suscep-
tible to tetracyclin, while a resistance against the same antibiotic characterized a 
species (C. seminale) that was clearly not multiresistant (Funke et al., 1997). 
One species, C. resistens, even got its name from its characteristic multi-
resistance (Otsuka et al. 2005). As concerns penicillin resistance, it is very un-
likely that coryneforms were producing β-lactamase (Martinez-Martinez et al., 
1996). Several lines of evidence report high resistance of coryneforms to 
macrolides and lincosamides (Fernandez et al. 2001; Funke et al. 1997; 
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Martinez-Martinez et al. 1996; Soriano et al. 1995; Ubaldi et al. 2004). 
Macrolide and lincosamide resistance occur together in MLSb (Macrolide-
Lincosamide-Streptogramin B) resistance pattern, as suggested by Rosato et al. 
(2001). As concerns nitrofurantoin, low MICs have been reported, so far 
(Soriano et al., 1995; Riegel et al., 1995). It seems pertinent to fluoroquinolone 
susceptibility that Corynebacterium sp. lack Topoisomerase IV (Sierra et al., 
2005), the enzyme that is the main target of trovafloxacin, levofloxacin, 
ciprofloxacin and norfloxacin, and a secondary target of gatifloxacin and 
sparfloxacin (Takei et al., 2001). Theoretically, lack of Topoisomerase IV 
should grant partial intrinsic resistance to fluoroquinolones. 
Hence, possible differences in coryneform composition of patients’ and 
controls’ microbiota as well as their role in etiopathogenesis of prostatitis are 
not finally elucidated. Moreover, as their susceptibility patterns are not uniform, 
the testing of prostatitis-associated strains would provide information for phy-
sicians who implement empiric antibacterial therapy. 
 
 
2.8.2.5. Mycoplasmas in case of prostatitis 
 
Mycoplasmas are the smallest freely living bacteria that are classified into 
Mollicutes because they have no cell wall. It is believed that Mollicutes prob-
ably derived from lactobacilli, bacilli or streptococci by losing cell wall and 
some biosynthetic pathways until they became the smallest and simplest free-
living and self-replicating cells of today (Razin et al., 1998; Woese et al., 1980).  
More than third of prostatitis patients harbor some Mollicutes (Corradi et al., 
1992). Urologically relevant species have been considered Ureaplasma urealy-
ticum, U. parvum, Mycoplasma genitalium, and M. hominis. These bacteria 
seem at least mildly harmful because of associations with decreased sperm 
quality and OxS (Weidner et al., 1978; Berger et al., 1989; Lin et Lu 2007; Su-
gata et al., 1987; Weidner et Anderson 2008; Potts et al., 2000). Yet, reviewers 
from last three decades have stated that the relations between prostatitis and 
mycoplasmas have not been finally elucidated and there are probably significant 
differences between species (Ludwig et Weidner 1995, Weidner et al., 1978; 
Taylor-Robinson et al., 2002; Bartoletti et al., 2007). 
Although associated with urethritis rather than prostatitis, M. genitalium was 
more common than C. trachomatis or N. gonorrhoeae in prostatitis patients also 
(Cao et al., 2003; Taylor-Robinson 2002) yet it has been found from a healthy 
man as well (Takahashi et al., 2006). M. hominis is quite infrequent in male ge-
nital tract (Lin et Lu, 2007; Szöke et al., 1998; Takahashi et al., 2006) and is 
considered not relevant to prostatitis although it may affect semen parameters 
adversely (Gdoura et al., 2007).  
During the last decade a novel species U. parvum was separated from U. 
urealyticum that was referred to as Ureaplasma urealyticum biovar 1 or B or 
parvo before 1999 (Robertson et al., 2002; Kong et al., 1999). This species has 
been found from 23% of healthy men (Takahashi et al., 2006) and has been re-
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searched mostly in association with urethritis. Earlier studies have frequently 
reported the prevalence of U. urealyticum without differentiating its biovars and 
therefore in these studies it may actually include U. parvum as well (Yoshida et 
al., 2007; Martin 2008). No studies of U. parvum in prostatitis patients have 
been available yet.  
According to a recent review (Martin, 2008), U. urealyticum is considered a 
pathogen of male urinary tract. The prevalence of U. urealyticum among pros-
tatitis patients has ranged wildly from 13,7% to 70,8% (Brunner et al., 1983; 
Yan et al., 2003, Corradi et al. 1992; Weidner et al., 1980) while among healthy 
men from 3% to 22% (Zeighami et al., 2007, Takahashi et al., 2006 and 
Weidner et al., 1980, respectively). U. urealyticum has been associated with 
higher levels ROS in semen, while there was no direct association with WBC 
concentration (Potts et al., 2000). It has been reported that ureaplasmas have 
good protection from host defenses and antibiotics by virtue of forming a bio-
film (Garcia-Castillo et al., 2008). 
Hence, the association of different mycoplasma species with prostatitis 
needs elucidation in further studies.  
 
 
2.8.3. Anatomic and traumatic 
 
Two major anatomic abnormalities might have initiated and propagated prosta-
titis: obstruction and reflux. Obstruction of the lower urinary tract caused by 
either bladder neck hyperplasia, benign prostatic hyperplasia, external sphincter 
dyssynergia, urethral stricture, meatal stenosis or even phimosis can cause high 
pressure dysfunctional voiding (reviewed by Nickel, 2002). That may be as-
sociated also with calcifications of urethral valves due to the uric acid crystals 
and a purine-rich diet (Mueller et Marshall 1983; Motrich et al. 2006) or patho-
logical spasm (Hellstrom et al. 1987). The high pressure turbulence caused by 
such obstruction changes the flow characteristics of urine through the urethra, 
creating currents and back eddies that can literally drag bacteria from the distal 
urethra into the area of the prostatic urethra, a potential scenario exists for intra-
prostatic reflux. Urine with potentially harmful and toxic constituents (potas-
sium, immunogenic proteins, etc.) and/or microorganisms passing through or 
dragged into the prostatic urethra can reflux into the prostatic ducts or even the 
acini. Prostatic ductal architecture is such that the peri-urethral area and the pe-
ripheral gland would be involved first, which appears to be the case in the 
pathogenesis of prostatic inflammation (reviewed by Nickel, 2002). In an ani-
mal model, urine reflux causes up-regulation of COX-2 in the prostate. COX-2 
participates in the synthesis of prostaglandins (including PGF2α) from poly-
unsaturated fatty acids and it is usually upregulated in case of inflammation (Liu 
et al. 2008). This theory for the initiation of prostatic inflammation and sub-
sequent symptoms would explain the benefits of a number of medical (e.g. 
alpha-blockers, finasteride) and surgical (e.g. incision of the bladder neck) 
therapies (Nickel, 2002). 
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  Repetitive perineal trauma may result in chronic perineal and pelvic pain as 
well. This was first described in medical literature with patients experiencing 
chronic perineal pain associated with horseback riding or riding on hard, 
wooden seats in poorly suspended buggies. This has been described more re-
cently in long-distance bicycle riders, and clinicians are generally aware of this 
syndrome occurring in many truck, tractor and heavy equipment drivers. Most 
probably, this repetitive trauma affects the local perineal muscle and nervous 
system, perhaps even the vascular system (i.e. local ischemia). It has been even 
hypothesized that if the perineum is thought of as a limb, repetitive perineal 
trauma may result in a local reflex sympathetic dystrophy syndrome. This 
would explain the muscular, neurogenic and perhaps even vascular symptoms 
and signs associated with this variant of chronic prostatitis/chronic pelvic pain 
syndrome. It also suggests various avenues of treatment, primarily avoidance of 
potentially traumatic experiences (reviewed by Nickel, 2002). As concerns the 
dangers of bicycling, the danger may actually be limited to improper use and 
not normal use, as mentioned before (Asplund et al. 2007).  
 
 
2.8.4. Autoimmune 
 
Nickel (2002) has considered autoimmunity an unlikely initiator but a likely propa-
gator of CPPS. There is evidence that lymphocytes from some prostatitis patients 
proliferate (or secrete IFN-γ) in response to seminal plasma or its antigens, such as 
PSA (Motrich et al., 2005, Batstone et al., 2002; Ponniah et al. 2000; Alexander et 
al. 1997). John et al. (2001) has discovered that there were large numbers of intra-
acinar T cells in NIH IIIB patients and these T cells associated with changes in 
blood and ejaculate interleukin levels. Rudick et al. (2008) have shown the associa-
tion between pain and autoimmune prostatitis in mouse model. They investigated 
the development of antigen-induced CP/CPPS and pinpointed prostate as the source 
of the pain. This mouse model also suggested the contribution of spinal or supras-
pinal mechanisms to pain sensation because an analgesic effect was obtainable with 
gabapentin. Pertinent to CPPS sub-typing, Krieger et al., (2002) brought out that the 
symptoms of inflammatory CPPS tended to be worse than symptoms of non-in-
flammatory CPPS. 
 
 
2.8.5. Neuromuscular and neural 
 
The most unpleasant symptom of prostatitis is the sensation of pain. The rou-
tinely used concentration of leukocytes is not an adequate correlate of pain. 
Hence, in order to find better intervention strategies, it would be useful to iden-
tify which processes exactly are responsible for maintaining or exacerbating the 
chronic pelvic pain. Substance P (Tang et al., 2007, Meyer-Sieglen et Vera 
2004; Chen et al., 2005) and calcitonin-gene related peptide (CGRP) (Geppetti 
et al., 2008) can be the important mediators of pelvic pain. Animal models sug-
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gest the presence of spinal component and an important role for substance P 
secretion resulting in a cascade of MIF?, NGF?, COX-2? and that of c-fos? (a 
transcription factor and a proto-oncogene) so that the prostate damage will 
cause consequences in bladder as well (Meyer-Siegler et Vera, 2004; Vera et 
Meyer-Siegler 2004; Zhang et al. 2007). Preliminary data suggests that pain 
may be associated with NGF?, IFN-γ?, IL-2? and IL-10? (Miller et al., 2002) 
although there exists a partial disagreement with other results (Duan et Yang, 
2005). 
 The cross-sensitization in spinal level has been published as an explanation 
for variability of CPPS symptoms (Malykhina 2007, Chen et al., 2005). Noci-
ceptive pathways can be suppressed by α-blockers, gabapentin, botulinum toxin, 
capsaicin and resiniferatoxin (Geppetti et al., 2008; Rudick et al., 2008; Tang et 
al., 2007; Chuang et al., 2006).  
 Hetrick et al. (2003 and 2006) has analyzed pelvic floor muscles of prostati-
tis patients and found, among other pelvic muscles, increased tension in levator 
ani and coccygeus muscle. The muscles of CPPS patients tended to have in-
creased prebaseline resting tonicity but weaker endurance contraction. Peng et 
al., (2009) have hypothesized that frequent sex activities with ejaculation could 
cause accumulation of free radicals and lactic acid in prostatic muscles to the 
point of fatigue, inflammation and dysfunction. Other researchers (Berger et al., 
2007; Shoskes et al., 2008) have found increased tenderness also and a neuro-
muscular spasm in the distal urethra or sphincters has been suggested as a likely 
cause of prostatic urine reflux (Hellstrom et al., 1987). Hedelin and Jonsson 
(2007) have pointed out that cold might initiate a process initiating CP/CPPS. 
 
 
2.8.6. Genetic 
 
Arisan et al. (2006) found a genetic risk factor of CPPS – a manganese super-
oxide dismutase (Mn-SOD) polymorphism at nucleotide number 47. This poly-
morphism was associated with weaker defenses against OxS, thus linking ge-
netics with OxS. Among other things, defects of this antioxidant enzyme may 
be responsible for higher prostate cancer risk in smokers and in men with low 
long-term lycopene status as well as with early-onset prostate cancer (Iguchi et 
al, 2009; Mikhak et al., 2008; Arsova-Sarafinovska et al., 2008). 
The results of a cytokine polymorphism study by Shoskes et al. (2002) in-
dicated existence of two types of patients. One group had decreased IL-10; 
these were refractory to treatment with quercetin, an anti-inflammatory anti-
oxidant polyphenol compound. Elevated TNF-α discriminated NIH IIIA from 
NIH IIIB. Others had high levels of IL-10, these were not so responsive to anti-
inflammatory treatment. Hence, they concluded that IL-10 and TNF-α could be 
used to assess the potential effect of anti-inflammatory treatment.  
Liu et al., (2008) provided a genetic link between prostatitis and prostate 
cancer using an animal model where overexpression of Vav3 oncogene caused 
first chronic prostatitis and then prostate cancer.  
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2.8.7. Hormonal 
 
Androgens have been long time pertinent to prostatitis research. Although an 
early study of Yunda et Imshinetskaya (1977) indicated that most of the prostatitis 
patients had considerable reduction in testosterone excretion, a recent study of Di-
mitrakov et al. (2008) reported elevated levels of androgens instead, and 
diminished levels of glucocorticoids and mineralocorticoids in prostatitis patients. 
Symptoms correlated with 17-hydroxyprogesterone, aldosterone and, inversely, 
with cortisol levels. The authors associated such situation with dysfunctioning 
enzyme CYP21A1 (P450c21) that partially blocked the synthesis of mineralocor-
ticoids and glucocorticoids, and channeled the production towards the end of 
androgen synthesis. In addition, according to Mukaratirwa et Chitura (2007) 
uncastrated dogs have a higher prevalence of prostatitis and BPH. Also, androgen 
antagonists have been of benefit in an animal model (Seo et al., 2003). Reduction 
of anti-inflammatory signal in castrated rats has been shown by Quintar et al., 
(2006). They also indicated that castrated animals had an increased expression of 
TLR4 in prostate epithelial cell surface – a molecule that recognizes endotoxin of 
Gram-negative bacteria. 
Estrogens have been found relevant, too. Inflammation occurs also after ad-
ministering estrogens to adult rats (Seethalahkshmi et al., 1996; Harris et al., 
2007; Bernoulli et al., 2007). There are reports of laboratory rat prostatitis due 
to peri- or neonatal exposure to estrogens (Stoker et al, 1999; Naslund et al., 
2008). While testosterone seemed beneficial, estrogen antagonists did not seem 
to do any good to the rats (Naslund et al., 1998). In contrast to rats, humans 
have benefited from an estrogen antagonist: mepartricin was superior to placebo 
in a controlled trial (De Rose et al., 2004).  
 
 
2.8.8. Oxidative stress in prostatitis 
 
Oxidative stress (OxS) is a condition in which the delicate balance that exists 
between equally necessary pro-oxidants and antioxidants is skewed towards 
pro-oxidants (Halliwell et Cross 1994). This condition is characterized by an 
imbalance between increased exposure to free radicals, principally derived from 
oxygen, and antioxidant defenses, comprised of both small molecule weight 
antioxidants, such as glutathione (GSH), and antioxidant enzymes, such as 
superoxide dismutase (SOD). Free radicals can be generated endogenously from 
various sources (for example, mitochondria and oxidative burst during phago-
cyte activation) or derived from exogenous sources such as environmental to-
xins and cigarette smoke. Free radicals cause direct damage to critical biomo-
lecules including DNA, lipids and proteins. OxS is recognized as a prominent 
feature of many acute and chronic diseases including cancer, cardiovascular di-
sease, neurodegenerative disease, lung disease as well as the normal aging 
process.  
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2.8.8.1. Spermatozoa 
 
Maintaining a fine balance between reactive oxygen species (ROS) and anti-
oxidants is essential for sperm maturation and function (Drevet 2006). De-
pending upon the nature and the concentration of the ROS, either a beneficial or 
a detrimental effect on sperm function could be expected (Aitken, 1997). Sev-
eral studies have shown that peroxidase positive leukocytes in semen (mostly 
polymorphonuclear leukocytes and macrophages) produce large amounts of 
ROS. Although immature sperms may also contribute to ROS production at 
some extent, the leukocytes produce at least 1000 times more ROS than sper-
matozoa. Excessive ROS levels disrupt human sperm function by peroxidation 
of unsaturated fatty acids within the sperm plasma membrane, diminishing mo-
tility and leading to incompetence for sperm-oocyte fusion. Damage caused by 
ROS may also be targeted at DNA, ROS can cause chromatin cross-linking, 
DNA base oxidation, and DNA strand breaks. The latter may accelerate the 
process of germ cell apoptosis leading to decline in sperm counts associated 
with male infertility and deterioration of semen quality. While separated from 
the seminal fluid, the spermatozoa are very vulnerable to OxS because their 
plasma membranes contain large quantities of polyunsaturated fatty acids and 
their intracellular defense against ROS is negligible (de Lamirande et Gagnon, 
1995; Saleh et al., 2002; Aitken et al., 1991, Twigg et al., 1998, Agarwal et al., 
2003). Recently, the effects of microwave radiation emitted by cellular phones 
have caught scientific attention. Although not directly related to prostatitis, it 
seems relevant that mobile phone radiation interferes with antioxidant levels 
and motility of spermatozoa (Agarwal et al., 2008). 
 
 
2.8.8.2. Seminal fluid 
 
The seminal fluid usually protects spermatozoa from OxS with its huge anti-
oxidative properties because it normally contains high amounts of anti-oxidants 
like spermin, thiols, uric acid and vitamin C (Henkel et al., 2005). Nevertheless, 
leukocytes can breach even great antioxidative defenses if they produce huge 
amounts of ROS (Saleh et al., 2002; Tremellen 2008; Agarwal et al., 2003; 
Lemkecher et al., 2005). Inflammation in case of leukocytospermic prostatitis is 
a typical situation where excessive production of ROS within the genital tract 
system is very much elevated and can deprive the anti-oxidative protection sys-
tem (de Lamirande et Gagnon, 1995). It has been found that OxS may be 
present in semen of prostatitis patients even if the leukocyte counts are very low 
(Pasqualotto et al. 2000).  
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2.8.8.3. Systemic  
 
Investigations of systemic OxS in case of prostatitis are not numerous. In the 
studies of Lou et al. (2006) and Zhou et al. (2006) occurrence of systemic OxS 
has been observed in case of NIH II prostatitis. In blood plasma, they observed 
an increase of blood nitric oxide (NO) and malondialdehyde (MDA) and a 
decrease of vitamins C and E as well as β-carotene. In erythrocytes, a reduction 
in levels of antioxidant enzymes catalase, glutathione peroxidase and 
superoxide dismutase was registered. Their regression analysis revealed that 
during the course of disease the NO and MDA increased while antioxidant 
levels decreased. 
Systemic antioxidants are associated with skeletal muscles. In mice, vitamin 
E produced intramuscular anti-inflammatory effect (IL-6?, IL-1β?) in case of 
lipopolysaccharide stimulation (Huey et al., 2008). In the same time, at least 
some exogenic antioxidants (vitamin C, vitamin E, allopurinol) may disrupt the 
innate adaptation to exercise-related oxidative stress (SOD?, glutathione 
peroxidase?) (Gomez-Cabrera et al., 2005; Ristow et al., 2009). In fact, the 
changes in OxS parameters resulting from aerobic training (SOD?, 8-OHdG? 
and 8-EPI?) might explain why prostatitis patients benefit from exercise 
(Devries et al, 2008; Gomez-Cabrera et al., 2005; Giubilei et al., 2007) 
8-EPI deserves special mention, because it is a relevant metabolite of free-
radical oxidation, which is used as a marker of systemic oxidative stress. Ele-
vation of 8-EPI is found in case of atherosclerosis and metabolic syndrome 
(Kals et al., 2006) as well as in case of immune response directed against peri-
odontitis, which is a polyfactorial biofilm infection (Offenbacher et al., 2009). 
Systemic 8-EPI is secreted via urinary tract and 8-EPI is both cause and con-
sequence of neuromuscular activity near prostate. In more precise terms, 8-EPI 
is formed in urinary bladder muscle and mucosa in response to physiologic and 
pathologic stimuli (stretching of detrusor muscle, injury to urothelium, stimu-
lation of the nerves) and the same 8-EPI causes smooth muscle contractions in 
relatively low concentrations in human bladder (Jeremy et al., 1987; Maggi, 
1992; Tarcan et al., 2000). Hence, 8-EPI may be an important variable in the 
pathogenesis of prostatitis even if we consider prostatitis a process limited to 
the prostate and its immediate vicinity.  
OxS participates in the pathogenesis of prostatitis but the mechanisms are 
still poorly understood. Since Shahed et Shoskes (2000, 2001) have shown that 
OxS in semen is linked to pain susceptibility (more precisely, inhibition of 
opioidergic antinociceptive mechanisms) it became plausible that OxS may be 
an element of major importance in the pathogenesis of chronic pelvic pain. 
 
 
2.9. Diagnostic procedures  
 
The most common (routinely used) diagnostic measures are as follows: vali-
dated NIH-CPSI questionnaire for quantifying subjective symptoms, digital 
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rectal examination (DRE), and measuring concentrations of WBC-s and aerobic 
cultivable bacteria from prostate-specific secretions (semen, EPS or VB3). 
Some other methods can be used as well – other questionnaires, ultrasound, 
measuring flow of urine and checking for underlying STDs. 
No unified diagnostic scheme has been proposed to date since several stu-
dies have shown controversial results. 4-glass test is a ‘gold standard’ in theory 
but in practice, it does not see much use, because it is just too cumbersome and 
expensive, and, hence, in practice a simpler 2-glass test is used (Kiyota et al., 
2003; Nickel et al., 2006). As concerns detection of inflammation in prostate 
specific specimens, according to Krieger et al., (2003) measuring inflammation 
from different materials (semen, VB3, EPS) was not equivalent because the 
measured concentrations of inflammatory cells did not correlate to each other. 
At the same time, measuring different materials increased sensitivity and 
specificity (Krieger et al., 2002; 2003). As concerns detection of causative 
agents, doctors diagnose bacterial prostatitis according to extant classification: 
the prostatitis is bacterial if and only if the patient is infected with traditional 
uropathogens (Gram-negative aerobic rods or enterococci). Other Gram-positive 
organisms in semen, EPS or VB3 have been usually considered as commensals 
although Shahed et Shoskes (2000) have suggested that those ‘commensals’ 
might actually be pathogens, too. Whether and how relevant the Gram-positive 
organisms are in the etiology and pathogenesis of prostate has been a good 
question without a good answer (Naber, 2008).  
In addition to aforementioned diagnostic measures, there is a multitude of 
immunological and biochemical markers that have been investigated. A long list 
of biomolecules has been researched in the context of prostatitis (Table 4). The 
study by Penna et al. (2007) is of special interest because it compared an im-
pressive list of cytokines and found that IL-8 was the strongest correlate of 
prostatitis. Seminal IL-6 was another good marker of inflammatory prostatitis 
(Orhan et al., 2001; Kopa et al., 2005) as shown also by our previous study 
(Korrovits et al., 2006). Although promising, the cytokines are not introduced 
into clinical practice yet. 
As concerns measuring blood flow of the prostate, the results have been 
contradictory (Neimark et al., 2000; Cho et al., 2000). According to Shoskes et 
al., (2007) calcifications in the prostate (detected by ultrasound) associated with 
bacteria and more WBC-s but were mutually exclusive with pelvic floor spasm 
and sensitization. 
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Table 4. Markers of prostatitis under investigation 
 
Marker of 
CPPS Specimen Reference 
IgA? upon 
exacerbation semen Kastner and Jakse, 2003; John et al., 2003 
IgG? upon 
healing  semen Kastner and Jakse 2003; 
K+ sensitivity N/A Parsons et Albo 2002, Hassan et al., 2007. It was not a good marker according to Yilmaz et al., 2004. 
IL-1β ?  EPS Alexander et al., 1998; Orhan et al., 2001 
IL-2 ?  EPS Li et al., 2006; Duan et Yang  2004 
IL-8 ?  EPS Hochreiter et al., 2000; Orhan et al. 2001; He et al., 2004; Li  et al., 2004 and 2006; Penna et al., 2007  
IL-6 ?  EPS Orhan et al., 2001; Koval'chuk et al., 2007; Penna et al. 2007; Stancik et al., 2008 
IL-10 ?  EPS Duan et Yang 2004 
IL-10 ?  EPS Li et al., 2004 
IL-4 ?  serum Li et al., 2006 
TNF-α ?  EPS Alexander et al., 1998; Nadler et al., 2000; Orhan et al., 2001; He et al., 2004; Motrich et al., 2006; Li et al., 2006 
IFN-γ ?  EPS Motrich et al., 2006; Ding et al., 2006 
TGF-β ?  EPS Ding et al., 2006 
NO ? semen Motrich et al., 2006 
CRP ? EPS Li et al., 2007 
CCL-1 ? semen Penna et al., 2007 
CCL-2 ? EPS Desireddi et al., 2008 
CCL-3 ? Semen, EPS Penna et al., 2007, Desireddi et al., 2008 
CCL-4 ? semen Penna et al. 2007 
CCL-17 ? semen Penna et al., 2007 
CCL-22 ? semen Penna et al., 2007 
CXCL5 ? EPS Hochreiter et al., 2000 (NIH IIIA) 
Mg ? semen Edorh et al., 2003; Mg was not a good marker according to Colleen et al, 1975. 
Zn ? VB3, semen 
Canale 1986, Kavanagh et al., 1983; Zn was not a good 
marker according to Zaichick et al. 1996 or Colleen et al.¸ 
1975 
Citrate ? EPS 
Zdrodowska-Stefanow et al.,. 2008; Kavanagh et al., 
1982; Chen et al., 2007. Total citrate output ? – Comhaire 
et al., 1989. 
Prostatic 
stones prostate Geramoutsos et al., 2004; Shoskes et al., 2007 
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2.10. Treatment options 
 
There is currently no standard treatment for CP/CPPS, and there are country-
specific variations in prostatitis treatment. Usually, prostatitis is treated with 
fluoroquinolone antibiotics, and this tradition seems to apply for any kind of 
prostatitis. Of prescription drugs, α-blockers and certain other antibiotics (TMP/ 
SMX and tetracyclines) are common as well. In addition to the above-
mentioned drugs, men with CPPS most probably consume over-the-counter 
anti-analgesics and herbal supplements. Unlike routinely used ones, the experi-
mental therapies are numerous (Table 5).  
 
 
2.10.1. Antibacterial agents 
 
Antimicrobial agents and especially fluoroquinolones are the most popular 
drugs for prostatitis treatment due to their good penetration to prostate tissue. 
Fluoroquinolones have been suggested for initial treatment of NIH I, NIH II, 
NIH III and NIH IV, that is any prostatitis category (Nickel, 2000; Murphy et 
al., 2009). According to both clinical experience and an open-label study by 
Nickel et al. (2001), CP/CPPS patients have frequently a positive treatment re-
sponse with fluoroquinolone therapy (reviewed by Murphy et al., 2009). At the 
same time, in a couple of controlled studies their effect has been comparable to 
placebo (Nickel et al., 2003; Alexander et al, 2004) and several papers indicate 
overuse (Ku et al., 2003; Taylor et al., 2008; Duclos et al., 2007). On the other 
hand, several lines of evidence suggest that fluoroquinolones have immuno-
modulatory properties as well that could influence therapeutic effect (Zhang et 
Ward 2007; Lahat et al., 2007, Dalhoff 2005, Williams et al., 2005; Takeyama 
et al. 2007). When compared to consumption of fluoroquinolones, the turnover 
of other antibiotics seems moderate. A minority of doctors uses tetracycline as 
primary or secondary treatment (Kiyota et al. 2003) while TMP/SMX is a first 
line agent in Canada (Nickel et al., 1998). Szöke et al. (1998) used amoxicil-
lin/clavulanic acid or clindamycin and Magri et al. (2007) used a 
fluoroquinolone and a macrolides in a combination treatment targeted against 
unusual or traditional pathogens that caused prostatitis. 
Despite unclear etiology of prostatitis and paucity of evidence-based sug-
gestions for antibacterial treatment, susceptibility patterns of potential causative 
agents must be recorded in order to improve the extant empirical treatment of 
inflammatory prostatitis. 
 
 
2.10.2. α-blockers 
 
α-blockers relax smooth muscles and inhibit nociception. Contrary to anti-
biotics, five out of six controlled studies justify the use of α-blockers (Cheah et 
al., 2003; Mehik et al., 2003; Sivkov et al., 2005; Nickel et al., 2004; Alexander 
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et al, 2004; Evliyaoğlu et Burgut, 2002), a class of drugs originally designed for 
high blood pressure treatment. Yet the results regarding the combinations of 
fluoroquinolones and a-blockers have produced divergent results (Ye et al., 
2008, Kulovac et al., 2007, Jeong et al., 2008; Barbalias et al., 1998).  
 
 
2.10.3. Anti-inflammatory agents 
 
Concerning treating prostatitis, the researched anti-inflammatory treatments 
have included glucocorticosteroids, COX inhibitors, herbal products, and even 
leukotriene inhibitors. Both zafirlukast and prednisolone were clearly not 
superior to placebo (Goldmeyer et al., 2005; Bates et al., 2007). Pollen extracts 
and quercetin have been successful in controlled studies (Elist et al., 2006, 
Shoskes et al., 1999). Pollen extract can suppress pro-inflammatory cytokines 
and mast cell degranulation (Asakawa et al., 2001; Ishikawa et al., 2008; 
Nakajima et al., 2009). It is prescribed in Japan for prostatitis about as 
frequently as antibiotics (Kiyota et al., 2003). Much more is known about 
quercetin. In addition to before mentioned properties of pollen, the other 
pertinent properties of quercetin include improving the function of endothelium, 
being a potent inhibitor of myeloperoxidase while not interfering with adaptive 
responses to OxS due to exercise (Okoko et Oruambo, 2009; Park et al., 2008; 
Romero et al., 2009; McAnulty et al., 2008; Gomez-Cabrera et al., 2005). In 
general, phytotherapy seems as the most promising kind of anti-inflammatory 
treatment. 
 
 
2.10.4. Other pharmacological treatment modes 
 
Finasteride, an inhibitor of 5-α-reductase, is a component in a multimodal thera-
py (or for patients with co-occurring BPH) rather than a primary treatment op-
tion (Kaplan et al., 2004; Nickel et al. 2004; Nickel, 2007). Neuronal desensiti-
zation therapy is yet highly experimental but deserves attention. It relates to the 
concept of neurogenic inflammation. Resiniferatoxin only desensitizes afferent 
neurons while botulinum toxin paralyzes the prostate because it affect efferent 
neurons, too (Geppetti et al., 2008; Dinis et al., 2005; Cruz et Dinis 2007, Tang 
et al., 2007; Maria et al., 2005). Pentosan polyphosphate, a heparinoid sur-
factant, has been shown to relief pain and discomfort related to interstitial cysti-
tis. That drug has been used for treatment of prostatitis also (Wedrén 1989; 
Nickel et al. 2005). Pentosan polysulphate probably works by avoiding urothe-
lium damage caused by mast cell degranulation (Chiang et al. 2000). Glu-
tathione and anti-oxidant vitamins C, E and Q10 have been recommended for 
curbing OxS in prostatitis patients (Sheweita et al., 2005), although the risks 
associated with antioxidant supplementation should be weighted against the ex-
pected benefits (meta-analysis by Bjelakovic et al., 2008). 
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Table 5. Treatment options of chronic pelvic pain syndrome 
 
Treatment mode* References 
Antibiotics 
 Fluoroquinolones (0/2) Nickel 2002; Ku et al., 2005; Luzzi 2002 
 Macrolides Magri et al., 2007; Ku et al., 2005; Luzzi 2002 
 Tetracycline Paulson et al., 2006; Luzzi 2002 
 TMP/SMX Nickel et al., 1998; Luzzi 2002 
Alpha-blockers  
 
doxazosin, alfuzosin, tamsulosin, 
terazosin (5/6) 
Mehik et al., 2003; Nickel 2008; Ye et al., 2008; 
Cheah et al., 2003; Jeong et al., 2008; 
Anti-inflammatory agents and antioxidants 
 Lycopene Han et al., 2008 
 
NSAID-s, glucocorticoids, leukotriene 
antagonists (0/3; rofexocib – minor 
effect) 
Nickel et al., 2003; Goldmeyer et al., 2005; 
Bates et al., 2007 
 Quercetin (1/1) Shoskes et al., 1999 
 Pollen extract (2/2) Elist et al., 2006, Wagenlehner et al., 2009 
 
(Serenoa repens, Epilobium parviflorum, 
Chinese herbs) 
Capodice et al., 2005; Steenkamp et al., 2006; 
Chen et al., 2006. 
 Allopurinol Persson et al., 1996; Ziaee et al., 2006 
 Terpenes Lee et al., 2006 
Non-pharmacologic 
 Prostate Massage Nickel et al., 1999 
 Acupuncture (minor effect) Lee et al, 2008; Capodice et al., 2005 
 TUMT, TURP or TUNA (0/1) 
Kastner et al., 2004; Barnes et al., 1982, 
Leskinen et al., 2002 
 Biofeedback and pelvic muscle training Cornel et al., 2005; Nadler 2002 
 Distal urethral web surgery Vega et al., 2002 
 Hot sitz baths Drach, 1975; Ku et al., 2005 
 Laser Capodice et al., 2005; Kozdoba et al., 2007 
 Shockwave therapy Zimmermann et al., 2008 
 Aerobic exercise (1/1) Giubilei et al., 2007 
 Electromagnetic therapy (1/1) Rowe et al., 2005 
 
Transcutaneous Electrical Nerve 
Stimulation (TENS) Sikiru et al., 2008 
 Myofascial physical therapy Fitzgerald et al., 2009 
Other substances 
 Botulin Maria et al., 2005; Cruz et al., 2007 
 Finasteride (2/2) Kaplan et al., 2004, Nickel et al., 2004 
 Pentosan polypsulphate (minor effect) Wedrén 1987; Nickel et al., 2005 
 Phosphodiesterase inhibitor Esilevskiĭ et al., 2005 
 Mepartricin 1/1 De Rose et al., 2004 
 
* – in brackets the ratio of successful/total of controlled studies have been shown, if 
any. 
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2.10.5. Non-pharmacological treatments 
 
There are several traditional or very experimental non-pharmacological treat-
ment modes (Table 5). The most common non-pharmacological treatments are 
psychotherapy and prostate massage (Yang et al., 2008). A simple experimental 
treatment is an aerobic training that improved the health of the patients when 
compared to non-aerobic training used as placebo (Giubilei et al., 2007). Acu-
puncture is another successful placebo-controlled non-pharmacologic treatment 
(Lee et al., 2008). Transurethral needle ablation (TUNA) was promising in 
preliminary study but failed in controlled study (Leskinen et al., 2002). Other 
experimental options include transurethral resection of the prostate (TURP, 
Nickel, 2000); transurethral microwave therapy (TUMT, Kastner et al., 2004); 
surgical resection of distal urethral web (Vega, 2000); shock wave therapy 
(Zimmermann et al. 2008). Adequate sexual activity has seemed as a factor that 
protects from prostatitis (Wallner et al., 2009), and Branigan et al. (1994) has 
suggested that frequent ejaculations in the background of antibiotic treatment 
can be beneficial. On the other hand, frequent masturbation or having multiple 
partners have been identified as prostatitis risk factors (Gao et al., 2007; 
Bartoletti et al., 2007) and Peng et al., (2009) have explained how frequent eja-
culations may cause prostatitis. Since the drugs do not selectively help a patient 
to avoid the extremes of behavior and do not consider individual differences, it 
seems that counseling and self-help might contribute to patients’ welfare.  
 
* * * 
 
Hence, in spite of multiple studies on etiopathogenesis of NIH categories III and 
IV chronic prostatitis that have applied wide variety of methods, the existing 
data set is controversial and incomplete and thus additional studies are needed 
to clarify this issue.  
Previous research of our workgroup has indicated that inflammatory prosta-
titis is frequently associated with abundant polymicrobial microbiota in semen 
(higher frequency, intensity and diversity in terms of colonization) while it is 
not finally clear whether this colonization is a cause, a consequence or a side 
effect. Yet it is very likely that inflammatory prostatitis may be associated with 
dysbalance of genital tract microflora and therefore more focused studies tar-
geted on certain microbial groups of this microbiota are needed. In this thesis, 
we concentrated upon Corynebacterium sp. and morphologically related bacte-
ria as well as upon Mycoplasmatales in order to determine their etiological role 
in inflammatory prostatitis.  
In addition, previous studies have indicated that OxS participates in the patho-
genesis of prostatitis but the mechanisms are still poorly understood. Therefore, 
additional data are needed in order to see whether and exactly how OxS fits with the 
extant theories of prostatitis, and how it is linked with inflammation. To meet this 
challenge, we collected the complex data about OxS in its different forms 
(antioxidants versus oxidation products and pro-oxidants) and levels – local 
(seminal plasma and in the spermatozoa) and systemic (urine and blood). 
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AIMS OF THE RESEARCH 
 
The general aim of this study was to elucidate some factors and mechanism that 
are associated with chronic inflammatory prostatitis. We therefore attempted to 
clarify whether Corynebacterium sp. and Mycoplasmatales are etiological fac-
tors of prostatitis, and to observe possible associations between seminal micro-
biota, inflammation, and oxidative stress that could explain the pathogenesis of 
this disease. 
 
The specific aims were as follows: 
1)  To compare the prevalence and species composition of coryneform bacteria 
in semen of chronic prostatitis patients and controls. 
2)  To determine the susceptibility patterns of coryneform bacteria isolated 
from semen.  
3)  To compare the prevalence and species composition of mycoplasmas in se-
men of chronic prostatitis patients and controls by simultaneously com-
paring culture method with PCR. 
4) To assess aspects of oxidative stress (antioxidants, pro-oxidants and oxi-
dation products) in the organism of chronic prostatitis patients in the sys-
temic level as well as in seminal fluid and spermatozoa. 
5)  To detect possible associations between seminal microbiota, inflammation, 
oxidative stress, and basic semen parameters. 
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MATERIAL AND METHODS 
 
Table 6. Study subjects, microbial strains and performed investigations 
 
Group No of subjects/ 
strains 
Study description* No of sub-
jects/ 
strains in 
sub-groups
Presented in 
Papers: 
Individuals 
Healthy Men 99 men Screening and anti-
microbial susceptibil-
ity testing of coryne-
forms 
59 I, II 
Oxidative stress in 
prostatitis 
9 IV 
Mycoplasmas in 
prostatitis 
40 III 
Men with NIH 
IV prostatitis 
(>0,2M 
WBC/ml) 
54 men Screening and anti-
microbial susceptibil-
ity testing of coryne-
forms 
30 I, II 
Oxidative stress in 
prostatitis 
11 IV 
Mycoplasmas in 
prostatitis 
24 III 
Men with NIH 
IIIA prostatitis 
(>0,2M 
WBC/ml) 
58 men Screening and anti-
microbial susceptibil-
ity testing of coryne-
forms 
20 I, II 
Oxidative stress in 
prostatitis 
10 IV 
Mycoplasmas in 
prostatitis 
38 III 
Men with NIH 
IIIB prostatitis 
59 men Mycoplasmas in 
prostatitis 
59 III 
Microbial Strains 
Coryneform 
strains 
 
148 strains 
from 109 pa-
tients 
 
Screening and 
identification of 
coryneforms 
148 of 148 I 
Antimicrobial 
susceptibility testing 
of coryneforms 
62 of 148 II 
 
* – see also Fig. 2. 
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A 
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Fig. 2. A. Formation of study groups. B. Composition of study groups.  
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Prostatitis 
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No 
prostatitis  
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Prostatitis 
complaints 
No 
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NIH IIIA 
n=58 
NIH IIIB 
n=59 
NIH IV 
n=54 
Control 
n=99 
Objective 
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Subjective
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3. Subjects and study design 
 
Altogether 270 men participated in the studies (Table 6). The subjects were re-
cruited into the studies according to the NIH Classification of the Prostatitis 
Syndromes (Table 1, Fig. 2A). The cut-off points for detecting leukocytospermia 
were 106 WBC/ml according to WHO guidelines (WHO, 1999) and 2·105 WBC/ml, 
according to our previous study results (Punab et al., 2003) where the concent-
ration and the mean number of different microorganisms was compared against 
WBC concentrations in semen specimens using ROC curve analysis. As a result, 
we found that an alternative cut-off level of 2·105 WBC/ml has the most optimal 
sensitivity/specificity ratio to differentiate between men with or without signi-
ficant bacteriospermia. Exclusion criteria for study subjects were stated according 
to the suggestions of the NIH workshop on chronic prostatitis (National Institutes 
of Health Summary Statement, 1995). None of the men had received antimicro-
bial therapy within 3 months, and men of oxidative stress study had abstained 
from other medicines and vitamins for 2 weeks.  
 
 
3.1. Men in the study of coryneform bacteria 
 
This study recruited 109 men (Table 6, Fig. 2B) who participated in a prospec-
tive study Environment and Reproductive Health (EU 6th FP project QLRT-
2001–02911) (72 participants, mean age 18.6 ± 0.2 years old) or the prospective 
case-control study of chronic prostatitis (37 participants, mean age 32.8 ± 1.3 
years old). The mean age of prostatitis patients was 28.5 (SE ±0.62) years; the 
mean age of controls was 20.0 years (SE ±1.32) years (p<0.05).  
 
 
3.2. Men in the study of oxidative stress 
 
This study included initially 43 men who participated in the prospective study 
of the etiopathogenesis of chronic prostatitis (Table 6, Fig. 2B). Due to diffi-
culties in finding suitable men whose semen samples were large and concen-
trated enough (in many cases too few spermatozoa were available for bioche-
mical analyses after Percoll centrifugation) the specimens of 30 men were avail-
able for the complex analysis. The controls as well as NIH IV category prosta-
titis patients consulted a physician due to infertility of the couple or pro-
phylactic purposes. The mean age of prostatitis patients and controls was 
32.3±1.4 years and 31.2±2.6 years, respectively (p>0.05). 
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3.3. Men in the study of mycoplasmas 
 
This study involved 161 men who participated in the prospective study of the 
etiopathogenesis of chronic prostatitis (Table 6, Fig. 2B). The controls as well as 
NIH IV category prostatitis consulted a physician due to infertility of the couple, 
for prophylactic purposes or their partner’s chronic gynecological infections. 
Prostatitis patients were somewhat older than controls, as the mean age of the 
prostatitis patients was 34.2±0.57 years and that of controls 28.7±0.61 years. 
 
 
3.4. Ethical considerations 
 
Participation in the study was voluntary. Informed consent was obtained from the 
participants. All subjects were at least 18 years old. The studies were approved by 
the Ethics Review Committee on Human Research of the University of Tartu. 
 
 
4. Bacterial strains tested in vitro 
 
A total of 62 coryneform strains isolated from semen of prostatitis patients (36 
strains) and controls (26 strains) were analyzed with E-test antimicrobial sus-
ceptibility testing: Corynebacterium seminale (29 strains), Corynebacterium 
group G (8), C. jeikeium (7), C. striatum (4), Dermabacter hominis (4), Cellulo-
monas/Microbacterium sp. (4), Corynebacterium group F1 (2), Brevibacterium 
sp. (1), Turicella otitidis (1), Arthrobacter sp. (1), and C. mucifaciens (1).  The 
set of the bacteria determined for susceptibility testing consisted of as many as 
possible Corynebacterium group G, Arthrobacter sp. and C. jeikeium strains, 
because the first two associated with inflammation while the latter was of in-
terest because of possible multiresistance. Not in agreement with that intent, 
three of the four strains identified as Arthrobacter sp. were unavailable to 
testing because of storage problems. The rest of the strains were chosen ran-
domly. Groups of Corynebacterium sp. are designations of CDC (Centers for 
Disease Control and Prevention), while Cellulomonas/Microbacterium is a cate-
gory of API Coryne identification system. 
 
 
5. Specimens 
 
5.1. Semen 
 
The samples were obtained by masturbation and were collected in a sterile col-
lection tube. After ejaculation, the semen was incubated at 37°C for 25–45 min 
for liquefaction. The samples were processed within 1 h (including time spent 
on liquefaction). 
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5.2. Urine 
 
5.2.1. Urine samples for microbiological analysis 
 
The first-catch urine was collected into a sterile collection tube by patients in a 
private room near laboratories after they washed their glans penis with soap and 
water. The urine samples were microbiologically investigated in 36 randomly 
selected men (30 with and 6 without leukocytospermia) who participated in the 
study of oxidative stress. The samples were cultured within 1 h.  
 
 
5.2.2.  Urine samples for biochemical analysis 
 
Urine samples of 30 men who participated in the study of oxidative stress were 
subjected to biochemical analysis. Prior to the biochemical analyses, urine was 
frozen for duration less than one year. 
 
 
5.3. Blood 
 
Blood samples were obtained by venipuncture, serum was obtained by centri-
fugation at 3000g by 5 min and analyzed immediately (for hsCRP, IL-6, preal-
bumin, Fe, ferritin, and transferrin receptors using standard methods) or kept 
frozen at -70°C (for the rest of analyses). The exact methods for specific mar-
kers are specified further. 
 
 
6. Routine analyses of semen 
 
6.1. Cytological analysis of semen for detection  
of leukocytospermia 
 
Semen smears were made for detecting white blood cells (WBC). The smears 
were air-dried, Bryan-Leishman stained, and examined with the use of oil im-
mersion microscopy (magnification: x1000) by an experienced microscopist. 
Polymorphonuclear (PMN) leukocytes were differentiated from spermatids by 
the presence of segmented nuclei, bridges between lobes of nucleus, and spe-
cific granulation of the cytoplasm (Couture et al., 1976). The WBC concent-
ration in semen (CWBC) was calculated by using the known sperm concentration 
(as 106/mL) according to the following formula: 
 
number of WBCs counted · semen sperm concentration 
C _________________________________________________  
number of sperm counted  
 
WBC=
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One hundred round cells were counted twice, and their mean value was regis-
tered.  
 The counting of WBC-s was used to divide the patients with prostatitis 
symptoms between categories of NIH IIIA and IIIB, and the subjects without 
prostatitis symptoms between category NIH IV and controls, as well as to di-
vide the patients into subgroups with either severe or moderate leuko-
cytospermia (Fig 2A). 
 
 
6.2. Basic semen parameters 
 
The analysis of semen was performed according to WHO guidelines (WHO, 
1999). Semen volume was estimated by weighing the collection tube with the 
semen sample and subsequently subtracting the predetermined weight of the 
empty tube assuming 1g=1ml. Motility was assessed in order to report the num-
ber of motile spermatozoa (WHO motility classes A+B). Sperm concentration 
was assessed using the Neubauer haemocytometers. Total sperm count was 
calculated by multiplying semen volume by sperm concentration. A qualified 
laboratory technician performed all semen analyses. 
 
 
6.3. Detection of interleukin-6 (IL-6) in semen 
 
Interleukin-6 levels of seminal plasma (100 µl of specimen was required for the 
assay) were measured in serum by chemoluminescent immunoassay 
IMMULITE 2000 Analyzer (Siemens Medical Solutions Diagnostics), ac-
cording to manufacturer’s instructions (Kit Catalog Number: L2K6P2). Assays 
were solid-phase, enzyme-labeled sequential chemoluminescent immunometric 
tests, which were performed automatically on the IMMULITE 2000 automated 
analyzer with 2 incubation cycles per 30 minutes, analytic sensitivity of 2 pg/ml 
for IL-6 and calibration range of up to 1000 pg/ml. Granules coated with anti-
bodies directed towards IL-6 were mixed with the samples. After washing, al-
kaline phosphatase-labeled antibodies were added. Free antibodies were washed 
away and chemoluminescent reagent was supplied. The reaction between alka-
line phosphatase and the chemoluminescent reagent resulted in light production, 
which was measured in the Immulite 2000 automated analyzer. The antibody 
used in assay is highly specific to IL-6 and has no cross-reactivity with IL-1α, 
IL-1β, IL-2, IL-4, IL-8, TNF-α or IFN-γ (IMMULITE 2000 IL-6, 2006).  
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7. Microbiological methods  
 
7.1. Preparation and cultivation of specimens 
 
Semen and urine samples were cultured quantitatively by “four corners” streak 
plate method to detect anaerobic, microaerophilic and aerobic bacteria within 1 
h from collection. Freshly prepared blood agar and chocolate agar, Wilkins-
Chalgren medium (Oxoid) supplemented with 5% horse blood, Wilkins-Chalg-
ren medium supplemented with 5% horse blood and GN supplement (Oxoid), 
MRS agar (Oxoid) and Gardnerella vaginalis-selective agar (Oxoid) were used. 
Aerobic (blood agar) and microaerobic (chocolate agar, MRS agar, and G. vagi-
nalis-selective agar in 10% CO2 atmosphere) cultures were incubated at 37 °C 
for 1–3 days and anaerobic cultures (Wilkins-Chalgren media in an anaerobic 
glove box) for 3–5 days. The gaseous environment of anaerobic glove box con-
sisted of 90% molecular nitrogen, 5% of carbon dioxide and 5% molecular 
hydrogen. 
 
 
7.2. Isolation and identification  
of cultivable microorganisms 
 
7.2.1. Coryneform bacteria 
 
Bacterial colonies that occurred on blood agar, chocolate agar, MRS agar, Wil-
kins-Chalgren medium (with or without GN supplement), and G. vaginalis-se-
lective agar were isolated and subjected to identification. Primary screening for 
coryneform bacteria was performed by Gram stain and subsequent microscopy 
as well as the catalase test. The coryneform strains were identified using the 
API Coryne biochemical identification system (BioMérieux) according to the 
manufacturer’s instructions with the exception of Corynebacterium seminale 
strains that were identified on the basis of β-glucuronidase test on blood agar 
with 4-methylumbelliferyl-β-D-glucuronide (MUG) supplement (Oxoid), which 
visualizes a positive reaction as a fluorescence near colonies under 254 nm 
ultraviolet light. In case of the urine strains, only C. seminale was identified to 
the species level. 
 
7.2.2.  Other bacteria 
 
Other microorganisms were identified mostly to genus level (Murray et al., 
1999). A latex test (Oxoid) was employed for discriminate Staphylococcus 
aureus from coagulase negative staphylococci (CONS). Novobiocin disks were 
used for identification of Staphylococcus saprophyticus. Streptococci and enter-
ococci were identified by the absence of catalase production and differentiated 
by fermentation of esculine. Group B streptococci were identified using a latex 
test (Oxoid). Gardnerella vaginalis was identified by its ability to grow on se-
14
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lective medium, characteristic morphology and negative catalase test. The anae-
robes were identified by absence of aerotolerance, growth on selective media, 
colony and cellular morphology, Gram stain reaction, some diagnostic disks 
(bile, brilliant green, colistin, vancomycin and kanamycin), rapid tests (indole 
and potassium hydroxide tests), fluorescence and ability to produce pigment. 
 
 
7.3. Susceptibility testing of coryneform bacteria 
 
The E-test susceptibility testing method was chosen since it has shown a good 
correlation of MICs with both broth microdilution and agar dilution in tests with 
Corynebacterium sp. (Funke et al. 1997). The E test strips (AB Biodisk) on ca-
tion adjusted Mueller-Hinton agar (Oxoid) were used as described elsewhere 
(Isenberg 2004) and following manufacturer's recommendations. Aid of a 
nephelometer (Becton Dickinson) was used for obtaining the suspensions with 
the desired turbidity (Mc Farland 0.5). Incubation at 37 °C at normal atmos-
phere was used for incubation (usually 24h, 48h for slow growers). Minimal 
inhibitory concentrations (MICs) for 8 antibacterial agents were determined. 
CLSI (Clinical and Laboratory Standards Institute, formerly NCCLS) inter-
pretive criteria for corynebacteria were used for penicillin G, trimethoprim-
sulfamethoxazole (TMP/SMX), doxycycline, erythromycin and clindamycin 
(Clinical and Laboratory Standards Institute 2005). Because no CLSI inter-
pretive criteria for corynebacteria exist with regards ampicillin-sulbactam, 
norfloxacin and nitrofurantoin, breakpoints for staphylococci were used for 
these antibiotics as suggested elsewhere (Clinical and Laboratory Standards 
Institute 2005; Funke et al. 1996; Otsuka 2005). The strains were considered 
susceptible (resistant) if their MICs were as follows: penicillin G ≤1 (≥4) 
µg/mL, ampicillin-sulbactam ≤8/4 (≥32/16) µg/mL, TMP/SMX ≤2/38 (≥4/76) 
µg/mL, doxycycline ≤4 (≥16) µg/mL, erythromycin ≤0.5 (≥2) µg/mL, clin-
damycin ≤0.5 (≥4) µg/mL, norfloxacin ≤4 (≥16) µg/mL and nitrofurantoin ≤32 
(≥128) µg/mL. The MIC values that were higher than susceptible but less than 
resistant were termed as intermediately resistant. 
 
 
7.4. Detection of mycoplasmas 
 
7.4.1.  Commercial kit method (Mycoplasma IST test) 
 
The Mycoplasma IST kit was applied to the semen samples of all 161 men to 
investigate Mycoplasma hominis and Ureaplasma urealyticum according to the 
manufacturer’s instructions, as described previously (Clegg et al., 1997). The 
16 wells of each IST kit strip contained a pH indicator and a lyophilized growth 
medium. When the inoculates of aforementioned Mollicutes in medium pro-
vided by manufacturer were inserted into the wells of the strips, then the 
changes due to pH change were interpreted as signs of growth as follows: from 
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pale yellow to amber for U10C broth, and from amber to red for arginine broth. 
Hence, the strips provided information on the presence or absence of M. ho-
minis and Ureaplasma sp., an estimate of the density of each organism (>104 
CFU) as well as antibacterial agent susceptibility data. 
 
 
7.4.2.  Polymerase chain reaction method (PCR) 
 
PCR was additionally used in the semen samples of 60 randomly selected men 
to investigate Mycoplasma genitalium, Ureaplasma parvum and U. urealyticum. 
DNA was extracted from 200 µl of semen using the High Pure PCR Template 
Preparation Kit (Roche Biochemicals), and 10 µl of extracted DNA was used 
for PCR. Primers MgPa1 and MgPa3 were used for specific M. genitalium ge-
nome amplification; they amplify a 281-bp segment of the 140-kDa adhesion 
protein gene (Jensen et al., 1991). The cycling parameters were as follows: 
95 °C for 2 min; 40 cycles at 95 °C for 30 s, 65 °C for 30 s and 72 °C for 25 s; 
and 72 °C for 5 min. Primers UMS-125 and UMA-226 were used for specific 
U. parvum genome amplification; they amplify a 403-bp segment of the 
multiple-banded antigen gene (Teng et al., 1994). Cycling parameters were as 
follows: 95°C for 2 min 30 s; 40 cycles at 95°C for 40 s, 60°C for 50 s and 72°C 
for 40 s; and 72°C for 5 min. PCRs were carried out using the thermal cycler 
Mastercycler (Eppendorf). Recombinant Taq DNA Polymerase (Fermentas) was 
used. Primers P6 and U8 were used for specific U. urealyticum genome ampli-
fication; they amplify a 1300-bp segment of the 16S rRNA gene (Robertson et 
al., 1992). Cycling parameters were as follows: 95°C for 3 min 30 s; 40 cycles 
at 95 °C for 1 min, 56 °C for 1 min 20 s and 72 °C for 2 min; and 72 °C for 5 
min. PCRs were carried out using the thermal cycler RoboCycler Gradient 40 
(Stratagene). Recombinant Taq DNA Polymerase (Fermentas) was used. The 
PCR products were separated by electrophoresis in a 2% agarose gel and vi-
sualized under UV light with ethidium bromide. 
 
 
8. Biochemical methods 
 
8.1. Semen sample preparation for biochemical analyses 
 
A discontinuous Percoll density gradient centrifugation was used to separate 
spermatozoa from leukocytes (Tucker et Jansen, 2002; Nakamura et al., 2002; 
Aitken et al., 1998). Percoll gradient centrifugation yields a highly motile frac-
tion of spermatozoa relative to starting sample and removes seminal plasma and 
other cells (Mortimer, 1994) which remain in less dense fractions after gradient 
centrifugation (Makler et al., 1998). Jouan CR3i centrifuge and glass test tubes 
(dimensions 12x104 mm, volume 8 ml) were used for centrifugation as des-
cribed in producer's manual. The specimen was centrifuged to separate seminal 
plasma and spermatozoa at 300g for 10 minutes at +2°C, the pellet was re-
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suspended in saline and centrifuged once more. The pellet was resuspended in 
saline and processed in a discontinuous Percoll density gradient (30%, 50%, 
70% and 90% SIP). A Neubauer counting chamber (haemocytometer) was used 
for measuring the concentration of spermatozoa in the fractions, enabling to se-
lect the most spermatozoa-rich fraction for further analyses. The samples were 
diluted in saline to the density 106 spermatozoa/ml, stored for further analyses 
in liquid nitrogen and disrupted by quick freezing-thawing for several times. 
 
 
8.2. Detection of iron (Fe), zinc (Zn) and nickel (Ni) 
 
400 µl of suspended spermatozoa or seminal plasma was pipetted to HDPE 
plastic vessel and 4 ml of the ultra pure water was added. The concentrations of 
metal ions in the solution were determined using a Varian (Varian Inc. Scien-
tific Instruments, Mulgrave, Australia) Liberty II axial inductively coupled 
plasma atomic emission spectrometer (ICP-AES). The detection of metals was 
performed in accredited laboratory according to EN ISO 11885:1996 (Water 
quality – Determination of 33 elements by inductively coupled plasma atomic 
emission spectroscopy). 
 
 
8.3. Detection oxidative stress 
 
8.3.1. Detection of total antioxidative activity (TAA) 
 
Total antioxidative activity (TAA) of seminal plasma (dilution 1:20) was as-
sessed by using the linolenic acid test (LA-test). This test evaluates the ability 
of sample to inhibit linolenic acid peroxidation, which indicates ability of a 
sample to inhibit oxidation in a lipid-soluble environment The standard of lino-
lenic acid in 96% ethanol (1:100) was diluted in isotonic saline (1:125). 0.01% 
sodium dodecyl sulphate was added to 0.4 ml linolenic acid, diluted in isotonic 
saline and the sample. The incubation started by adding 100 µl FeSO4 (final 
concentration 200 µM) and the mixture was incubated at 37°C for 60 min. Then 
the reaction was interrupted by adding 0.035 ml butylated hydroxytoluene and 
the mixture was treated with 0.5 ml acetate buffer (pH 3.5) consisting of acetic 
acid glacial and sodium acetate trihydrate and heated with freshly prepared 1% 
thiobarbituric acid solution (TBA) at 80°C for 40 min. After cooling the mixture 
was acidified by adding 0.5 ml cold 5 M HCl, extracted with 1.7 ml cold 1-bu-
tanol and centrifuged at 3000g for 10 min and the TBA reactivity (as µM of 
malondialdehyde equivalents) of butanol fraction was measured spectrophoto-
metrically at 534 nm. The TAA of sample was expressed as inhibition by 
sample of LA-standard peroxidation as follows: [1 – (A534 (sample) / A534 
(LA as control)] x 100. The higher numerical value (%) of TAA indicates the 
higher TAA of sample. Peroxidation of LA-standard in the isotonic saline 
(without serum) served as a control. 
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8.3.2. Detection of total antioxidative status (TAS) 
 
TAS indicates the ability of a sample to inhibit the ROS-mediated oxidation in 
an aqueous environment. To measure total antioxidative status (TAS) of blood 
serum, seminal plasma and in spermatozoa we used a commercially available 
kit (Randox Laboratories Ltd.). To measure total antioxidative status (TAS) of 
blood serum, seminal plasma and in spermatozoa we used a commercially avail-
able kit (Randox Laboratories Ltd.). This method is based on the inhibition of 
the absorbance of the ferrylmyoglobin radicals of 2,2’-azinobis-ethylbenzo-
thiazoline 6-sulfonate (ABTS+) generated by activation of metmyoglobin per-
oxidase with H2O2. The suppression of the absorbance of ABTS+ radicals by 
sample depends on TAS of the sample under investigation (Rice-Evans et Mil-
ler, 1994). The assay procedure was as follows. To 0.02 ml of blood serum 
(blank was ultrapure water) and standard (6-hydroxy-2,5,7,8-tetramethylchro-
man), 1 ml of chromogen (metmyoglobin) solution was added, mixed well and 
initial absorbance was read. Then 0.2 ml of substrate (hydrogen peroxide in 
stabilized form) was added, mixed, incubated at 37oC and absorbance was read 
exactly after 3 minutes at 600nm. The TAS values are expressed as Trolox units 
(mmol/L). 
 
 
8.3.3. Detection of ascorbic acid (AsA) 
 
Ascorbic acid is a major antioxidant of the aqueous environment. Ascorbic acid 
(AsA) is oxidized by 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, a stable free 
radical (TEMPO) to dehydroascorbic acid (DAsA). The latter condenses with o-
phenylenediamine (OPDA) to form a quinoxaline derivative that absorbs light 
at 340 nm. The change in absorbance at 340 nm is proportional to the concent-
ration of AsA in the specimen. Briefly, heparinized plasma or seminal plasma 
(0.025 mL) and 0.2 mL of TEMPO solution (200 mg/L in phosphate buffer, pH 
6.5) were incubated at 37°C for 5 min. Then 0.085 mL of the OPDA solution 
(500 mg/L in phosphate buffer, pH 6.5) was added and the absorbances at 
340 nm were determined every 60 s for 3 min. We used the phosphate buffer as 
a reagent blank to correct for any non-specific absorbance. We used a 25 mg/L 
AsA calibrator to calculate the concentration of AsA in the specimens (Ihara et 
al., 2000). TEMPO, OPDA dihydrochloride and AsA were obtained from Sig-
ma Chemical. 
 
 
8.3.4. Detection of glutathione and oxidized glutathione 
 
Antioxidative activity of the major antioxidant glutathione (GSH) is mediated 
by the – SH (sulfhydryl) functional group of the molecule. Total glutathione and 
oxidized glutathione were measured by using the method described earlier 
(Griffith, 1980). The samples were deproteinated with 10 % solution of meta-
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phosphoric acid. The equal volume of the metaphosphoric acid was added to the 
sample and mixed vigorously. The mixture was allowed to stand at room tem-
perature for 5 min and centrifuged at 3000 g for 5 min. In cases where the assay 
was not performed immediately, the supernatant was carefully collected and 
stored at –20ºC. Glutathione content was measured by adding 0.005 ml of 
triethanolamine 4M solution in water to 0.1 ml of sample and mixed imme-
diately. Thereafter, the sample was divided into two parts. For assay of oxidized 
glutathione (GSSG), reduced glutathione (GSH) was derivatized by adding 0.1 
ml 2-vinylpyridine in 1 mM ethanol to first part of the sample, mixing on a 
vortex mixer and keeping at room temperature for 1 h. To determine the content 
of GSSG, 0.2 M sodium phosphate buffer (pH 7.5) containing 0.01 M EDTA, 
0.5 U glutathione reductase and 0.3 mM NADPH was added to the 0.1 ml of 
derivatized sample and mixed immediately. The enzymatic reaction was ini-
tiated by addition of 0.1 ml of 1 mM 5,5’-dithio-bis-2-nitrobenzoic acid in 0.2 
M sodium phosphate buffer (pH 7.5) containing 0.01 M EDTA (Griffith, 1980). 
The change in optical density was measured after 10 min at 412 nm spectro-
photometrically. The glutathione content was calculated based on a standard 
curve generated with known concentration of glutathione. Amount of GSH was 
calculated as a difference between the total glutathione and GSSG (total 
glutathione – GSSG = GSH). The glutathione content was expressed as µg/ml 
of sample or as glutathione redox ratio (GSSG/GSH).  
 
 
8.3.5. Detection of 8-isoprostanes (8-EPI) 
 
8-isoprostanes (8-EPI) are major stable end-products ROS-mediated prostanoid 
oxidation. We used the method with what we had previously measured the 
content of 8-EPI in urine of healthy humans (Kullisaar et al., 2003). This assay 
is a competitive enzyme-linked immunoassay (ELISA) for determining levels of 
8-EPI in biological samples (BIOXYTECH 8-Isoprostane Assay, Cat. No. 
21019). Briefly, 8-EPI in the samples or standards competes for binding (to the 
antibody coated on the plate) with 8-EPI conjugated to horseradish peroxidase 
(HRP). The peroxidase activity results in color development when the substrate 
is added. The intensity of the color is proportional to the amount of 8-EPI-HRP 
bound and inversely proportional to the amount of 8-EPI in the samples or stan-
dards. The urinary concentrations of isoprostanes were corrected by urinary 
creatinine concentrations to account for the differences in renal excretory func-
tion. 
8.3.6. Detection of diene conjugates (DC) 
 
Lipid peroxidation results in the formation of diene conjugates, which are used 
as lipid peroxidation markers. Diene conjugates were measured according to the 
method previously described (Recknagel et Glende, 1984) with minor mod-
ifications (Starkopf et al., 1995). Briefly, samples (0.15 ml) + 0.15 ml 0.9% 
NaCl (reagent blank contains only isotonic saline) were incubated at 37 ºC for 
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30 min, 0.25% butylated hydroxytoluene (0.015 ml) was added and the lipids 
were extracted by heptane/isopropanol (1:1, whole volume 1.8 ml). Then the 
samples were acidified by 5M hydrochloric acid (0.5 ml). After extraction by 
cold heptane (1.6 ml), samples were centrifuged (for 5 min at 3000 rpm) and 
absorbance of heptane fraction was measured spectrophotometrically at absor-
bance maximum at 234 nm. 
 
 
8.3.7. Detection of 8-Hydroxy -2´- Deoxyguanosine (8-OhdG) 
 
8-OHdG shows ROS-mediated damage to DNA. The BIOTECH 8-OHdG Kit is 
for quantitative measurement of 8-OHdG in tissue, serum, plasma and urine 
resulting from oxidative damage of DNA. The 8-OHdG monoclonal antibody 
and the sample or standard were added to a microtiter plate well that has been 
precoated with 8-OHdG. The 8-OHdG in the sample or standard competes with 
the 8-OHdG bound on the plate for the 8-OHdG monoclonal antibody binding 
sites. Therefore, higher concentrations of 8-OHdG in the sample solution leads 
to a reduced binding of the antibody to the 8-OHdG on the plate.  
 
 
9. Statistical analysis 
 
Statistical analyses were performed with the use of SigmaStat (Jandel Scienti-
fic) and Excel (Microsoft Corp, Redmond, WA, United States of America) soft-
ware programs. In the study of oxidative stress, the study groups were com-
pared with t-test (in case of normal distribution) and Mann-Whitney rank sum 
test (in case of non-parametric distribution). Spearman rank order correlation 
was used to find out correlations between different markers. In the study of 
coryneform bacteria, microbial counts were compared with Mann-Whitney rank 
sum test. The occurrence of microorganisms in different groups was compared 
with Fisher exact test. In the study of mycoplasmas, Fisher’s exact test, Chi 
square test and logistic regression analysis were used to compare the occurrence 
of mycoplasmas between the different study groups. Cohen’s kappa coefficient 
κ for diagnostic agreement was used to compare the two methods. p ≤ 0.05 was 
considered significant in all analyses. 
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RESULTS AND DISCUSSION 
 
10. Coryneform bacteria in semen  
of chronic prostatitis patients 
 
10.1. Prevalence of coryneform bacteria  
in male genital tract 
 
On the level or primary screening, no differences between patients and controls 
were found as coryneform bacteria were present in the semen of 38 (76%) in-
flammatory prostatitis patients (both NIH IIIA and NIH IV categories) as well as 49 
(83%) controls (p>0.05). The subjects had 0...6 (mean 1.3) different coryneforms 
present, 0...4 (1.4) in prostatitis patients and 0...6 (1.2) in controls (no statistical 
differences).. Since no difference was found also between NIH IIIa and NIH IV 
category patients (data not shown), these categories were analysed together. 
Substantial differences were revealed between prostatitis patients and cont-
rols on the species level. Two coryneform bacteria were significantly more fre-
quently found from prostatitis patients with severe inflammation than controls – 
Corynebacterium group G (33% vs. 2%, p=0.0003) and genus Arthrobacter 
(17% vs. 2%, p=0.03). In general, the most frequent species in male genital tract 
was Corynebacterium seminale, being present in 30 prostatitis patients and 34 
controls (Table 7). 
We compared the bacteria of semen with that of first-catch urine that enabled 
us to distinguish between urethral contamination and true microbiota of semen. 
Half of men (50%) harbored corynebacteria in both semen and urine, 22% of men 
harbored them in semen only and 3% in urine only. Their total concentration was 
greater in semen than in urine (median 5000 vs. 100 CFU per ml) yet the 
difference did not reach the level significance (p=0.053). Of urine strains, only C. 
seminale was identified to species level (present in 39% of men). 
Coryneform bacteria have been previously found from urogenital tract of 
both healthy men (Willen et al., 1996) and patients with prostatitis (Tanner et 
al., 1999; Riegel et al., 1995; Domingue et Hellstrom, 1998). It has been stated 
more than 30 years ago (Drach, 1974) that 12% of studied prostatitis cases were 
due to coryneform organism in pure culture or with associated bacteria. Cultur-
able coryneform species isolated from semen or expressed prostatic secretions 
include C. seminale (Riegel et al., 1995), C. singulare (Riegel et al., 1997), C. 
freneyi (Renaud et al., 2001), C. striatum/amycolatum, C. macginley, C. jei-
keium, Dermabacter hominis (Jędrzejczak et al., 2005) and even C. diphtheriae 
(Machado et al., 1989). Gardnerella vaginalis is a catalase negative coryneform 
that has been strongly associated with bacterial vaginosis in women. That 
microorganism occurred less frequently in our study than in some other studies, 
where G. vaginalis has been found in 19%…26% of semen specimens (Hillier 
et al., 1990; Virecoulon et al., 2005). Domingue et al. (1997) found Coryne-
bacterium group ANF and C. minutissimum from EPS, while Tanner et al., 
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(1999) found several species by PCR from the same material. Of the species 
found, C. genitalium and C. tuberculostearicum seemed to have affinity towards 
prostatitis, and unknown Corynebacterium sp. related to C. coyleae, C. imitans 
or C. seminale were found exclusively from prostatitis patients. Hence, earlier 
studies have associated prostatitis with different sets of Corynebacterium spe-
cies. Our results followed the suit. 
As concerns methodological aspects, biochemical identification with API 
Coryne is less exact than genotype-based methods (Roux et al., 2004). Some 
API Coryne bacterial groups may be polyphyletic, as Cellulomonas sp. and 
Microbacterium sp. are clustered into one category. Corynebacterium group G 
probably consists of several species since according to additional tests that were 
performed later, most of our Corynebacterium group G strains were fructose 
negative, which does not fit the description of Corynebacterium group G pro-
vided by von Graevenitz et Bernard (2006). The API identification profiles of 
our strains of this group were 6000325, 61003025, 6140325 and 1200325.  
 
 
10.2. Quantitative composition of seminal coryneflora 
 
We subsequently set a threshold limit of ≥104 CFU per ml to bacterial con-
centration in order to reveal possible differences between patients and controls 
at quantitative level. In control subjects, only four bacterial groups managed to 
outnumber this threshold: C. seminale, C. jeikeium, Corynebacterium sp. and 
catalase-negative coryneforms (Fig. 3). In prostatitis patients also Arthrobacter 
sp., Brevibacterium sp., Cellulomonas/ Microbacterium, Corynebacterium 
group F1 and Corynebacterium group G exceeded that treshold.  
 
Fig. 3. Quantitative differences in seminal coryneflora of inflammatory prostatitis pa-
tients and controls.  
The list of the different isolates that can be found in significant (>104 CFU/ml) quan-
tities from prostatitis patients is longer than the analogous list for controls.  
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In our prospective quantitative study with 6 media and 3 different environ-
ments, the coryneform species emerged as the most frequent group of micro-
organisms, in an agreement with our previous data (Punab et al., 2003; Kermes 
et al., 2003; Korrovits et al., 2006) as well as to the data of Hillier et al. (1990) 
who found them in 86% of semen specimens. According to our previous studies 
(Punab et al., 2003; Kermes et al., 2003; Korrovits et al., 2006), the seminal 
microflora of prostatitis patients differs significantly from that of controls since 
the total concentration and number of different microorganisms are much higher 
in the semen of prostatitis patients than in the controls. Hence, these data 
pointed out the idea of the polymicrobial nature of prostatitis. The present study 
has taken under examination one group of this microbial community and these 
data indicate that some coryneform species may appear a major component of 
this microbiota. 
 
 
10.3. Susceptibility of coryneform bacteria 
 
The minimal inhibitory concentrations and numbers of non-susceptible (resis-
tant plus intermediate) strains are presented in Table 1 at Paper II. All strains 
were susceptible to ampicillin-sulbactam and only a few were resistant to peni-
cillin G and TMP/SMX while nearly one third of strains were resistant or inter-
mediate to doxycycline (35%) and norfloxacin (29%), and more than half to 
clindamycin (63%), nitrofurantoin (62%) and erythromycin (53%). Similar 
susceptibility pattern was characteristic to the most common species, C. semi-
nale, most of its strains were resistant or intermediate to clindamycin, erythro-
mycin, norfloxacin and nitrofurantoin.  
The strains showing resistance to at least 3 antimicrobials belonged to 
Corynebacterium group F1, Corynebacterium seminale and Cellulomonas/ 
Microbacterium sp. One Cellulomonas/Microbacterium sp. strain was resistant 
to four (erythromycin, clindamycin, penicillin G and nitrofurantoin), one 
Corynebacterium group F1 strain to 3 (erythromycin, clindamycin, doxy-
cycline) and three C. seminale strains to three antimicrobials (erythromycin and 
clindamycin combined with norfloxacin, nitrofurantoin or TMP-SMX). In 
addition, 20 strains (12 C. seminale, four Corynebacterium group G, two D. ho-
minis, one C. striatum, and one Cellulomonas/Microbacterium sp.) were resis-
tant to two antimicrobials. A distinct co-occurring macrolide and lincosamide 
resistance pattern was common. The susceptibility of the strains originating 
from prostatitis patients and those of controls were compared (data not shown) 
and no significant differences were found. 
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Fig. 4. Susceptibility pattern of Corynebacterium group G.  
White – susceptible; striated – Intermediate; black – Resistant. 
 
 
The results of our study were in general agreement with the data of previous 
reports about frequent resistance among coryneform bacteria to several anti-
microbials. The available data describe mostly the invasive nosocomial pathogens 
and very scarce information exists concerning the mucosal strains yet they may 
become under certain conditions the source of infection. Since our strains 
originated from the male genital tract, we have tested their susceptibility mainly 
to antibiotics commonly used in andrological practice. Corynebacterium group G 
that was associated with prostatitis showed resistance to several antibacterial 
agents including norfloxacin that is commonly used for treatment of male genital 
tract infections (Fig. 4). Since treatment of prostatitis usually does not aim for a 
particular target, susceptibility of possible pathogens may give valuable 
information for choosing an antibiotic. Caution is advised for interpreting our in 
vitro data for the purpose of in vivo application. Relevant factors like prostate 
tissue penetration and biofilm associated resistance should be taken into account. 
Although bimodal spread of susceptibility (MIC either <0.5 or >4 µg/mL) to 
ciprofloxacin has been described (Fernandez et al. 2001), similar pattern did not 
appear in our study. Corynebacterium sp. did not display any level of universal 
intrinsic resistance to norfloxacin that could be expected from the absence of 
Topoisomerase IV in these bacteria. 
Resistance to β-lactam antimicrobials among the coryneforms varies, C. 
seminale, T. otitidis and Arthrobacter sp. have been more susceptible to peni-
cillin G than C. jeikeium, C. striatum, and D. hominis (Funke et al., 1996; Fun-
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ke et al., 1997; Radtke et al., 2001; Ubaldi et al. 2004). Our strains were highly 
susceptible, except Cellulomonas/Microbacterium group 
Our data corresponds to several studies that have shown a high macrolide 
and lincosamide resistance of coryneforms (Fernandez et al. 2001; Funke et al. 
1997; Martinez-Martinez et al. 1996; Soriano et al. 1995; Ubaldi et al. 2004) 
and MLSb resistance (a co-occurring resistance to Macrolide, Lincosamide and 
Streptogramin B) (Rosato et al. 2001). In our study, 16 strains (13 C. seminale, 
2 Cellulomonas/ Microbacterium sp. and 1 Corynebacterium group F1) showed 
concurrent resistance to erythromycin and clindamycin. 
Unlike earlier studies (Riegel et al. 1995; Soriano et al. 1995), in our study, 
C. jeikeium and C. seminale did not have low MICs of nitrofurantoin. Another 
discord with earlier reports was revealed in case of TMP/SMX that was highly 
active on the majority of the strains studied by us while weak or missing acti-
vity of it against C. striatum, C. jeikeium, D. hominis and T. otitidis has been 
described (Martinez-Martinez et al. 1996; Traub et al. 1998; Troxler et al. 
2001). Our strains were susceptible to TMP/SMX, which was declared as a 
drug of choice in Canada (Nickel et al. 1998). 
 Resistance to tetracyclines among corynebacteria is controversial – generally 
multiresistant species as C. jeikeium and C. amycolatum are relatively suscep-
tible, while C. seminale and C. striatum quite resistant (Funke et al. 1997; 
Martinez-Martinez et al. 1996). D. hominis, T. otitidis and Cellulomonas sp. 
(Troxler et al. 2001; Funke et al. 1997) have been susceptible. In contrast to 
these studies, our C. striatum strains were susceptible to doxycycline. 
 
 
11. Mycoplasmas in semen  
of chronic prostatitis patients 
 
11.1. Mycoplasmas detected by Mycoplasma IST test  
 
Mycoplasma IST test gave positive results in all studied groups – three 
prostatitis categories (NIH IIIA, NIH IIIB and NIH IV) and controls (Table 8, 
Fig. 2). M. hominis was found only in one NIH IIIB patient, in a low count (104 
CFU /ml). At the same time, ureaplasmas were found in nearly 20% of 
prostatitis patients and in 12% of controls using the Mycoplasma IST test.  
Mycoplasma IST and newer IST 2 tests have been implemented for ana-
lyzing mycoplasmas in male patients. Mycoplasma IST test has been reported to 
be superior to MycoFast All-In test for detecting M. hominis (Vázquez et 
al.,1995). While analyzing the patients with non-gonococcal urethritis using 
IST test, Kilic et al. (2005) found that 24 of 50 these men harbored U. urealy-
ticum, and eight of those 24 harbored M. hominis. In a study by Zdrodowska-
Stefanow et al., (2006) U. urealyticum was found in 8% of prostatitis patients 
while M. hominis was not found using IST 2 test – that corresponds to our data.  
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11.2. Mycoplasmas detected by PCR method 
 
A quarter of chronic prostatitis patients harbored mycoplasmas confirmed by 
PCR in their semen (Fig. 5). This proportion was even higher in case of inflam-
matory CP/CPPS (NIH IIIa) patients of whom one third were colonized by 
mycoplasmas, at the same time they were present only in 1 out of 25 healthy 
controls (4/11 vs 1/25; p=0.023).  
Using PCR, most of the ureaplasmas found using the IST test were re-
identified as U. parvum, which emerged as the most common species (Table 8). 
U. parvum was not found from healthy men but it was found from all prostatitis 
groups (NIH IIIA, NIH IIIB and NIH IV). One patient in NIH category IV had 
both Ureaplasma species. M. genitalium occurred only in NIH category IIIA 
patients.  
Previous investigators have found numerous mycoplasma species in humans. 
For certain species such as Ureaplasma sp., M. hominis and M. genitalium, the 
genital tract is thought to be the main site of colonization (Baseman et Trully 
1997, Uusküla et al., 2002). Apparently, U. urealyticum is the most widespread 
mycoplasma in the genital tract of both sexes, its reported prevalence in human 
semen varying from 10% to 40% (Keck et al., 1998). U. urealyticum has been 
related to non-gonococcal urethritis and prostatitis but it also quite frequently 
colonizes asymptomatic men (Keck et al., 1998, Potts et al., 2000). Unfortu-
nately, in most previous studies, no distinction was made between U. urealy-
ticum and U. parvum. U. parvum (formerly U. urealyticum biovar 1) was dis-
tinguished from U. urealyticum (Kong et al., 1999), and it has been shown in 
some studies that most ureaplasmas in semen may actually be U. parvum (Knox 
et al., 2003). A similar tendency could also be seen in our study, where U. par-
vum occurred more frequently among PCR-confirmed mycoplasmas than U. 
urealyticum and, interestingly, it was present only in prostatitis patients.  
M. genitalium is a probable cause of non-gonococcal urethritis (Jensen 
2004), and is associated with prostatitis (Kriger et Riley 2002). The prevalence 
rate of M. genitalium in a biopsy study of nonbacterial prostatitis patients was 
4% (Krieger et al., 1996) although some contradictory results can be found as 
well (Taylor-Robinson 2002). M. genitalium can affect fertility as it was shown 
to adhere to the spermatozoa, which became immotile when many M. genita-
lium were attached (Svenstrup et al., 2003). In our study, this species was as-
sociated with NIH category IIIa prostatitis patients.  
 
 
11.3. Impact of PCR on interpreting IST test results 
 
We found substantial agreement between the two methods used for the genus 
Ureaplasma: in 48/60 men both tests were negative and in 7/60 both tests were 
positive (κ=0.69, p=0.0007). As the exception, four men were IST positive but 
PCR negative while one man was IST negative but PCR positive.  
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A similar situation has been discussed by Stellrecht et al. (2004), who found 
some culture-positive but PCR-negative semen specimens, although they cul-
tured mycoplasmas on A7 agar instead of using the Mycoplasma IST test. Ras-
tawicki et al. (2004) found also some IST test positive but PCR and culture 
negative specimens and explained it with oversensitivity of IST test. In our 
study, the false-positive results may have been caused by other urease-positive 
microorganisms, as the IST test detects ureaplasmas by means of this enzyme. 
Despite of agreement between the methods, IST test does not enable diffe-
rentiation of U. urealyticum and U. parvum. As U. parvum was most common 
mycoplasma, and present only in prostatitis patients, there is an argument for 
using the PCR method instead of the Mycoplasma IST test. The IST test does 
not detect prostatitis-associated M. genitalium as well and it is another argument 
to suggest PCR method for detecting mycoplasmas in prostatitis patients.  
 
 
Table 8. Occurrence of mycoplasmas in semen 
 
Test 
Method 
  Positive specimens N, % 
Microorganism NIH IIIA NIH IIIB NIH IV Controls 
Myco-
plasma 
IST 
Ureaplasma sp. 8/38 (21%)  10/59 (17%) 6/24 (25%) 5/40 (12%) 
M. hominis 0/38 (0%) 1/59 (2%)  0/24 (0%) 0/40 (0%) 
PCR 
 
 
U. urealyticum 0/11 (0%) 1/20 (5%) 1/4 (25%)  1/25 (4%) 
U. parvum 2/11 (18%)*  3/20 (15%)***  1/4 (25%) 0/25 (0%)*,*** 
M. genitalium 2/11 (18%)** 0/20 (0%) 0/4 (0%) 0/25 (0%)** 
*,** p=0.087 (Fisher’s exact test); p=0.028 (Chi square test) 
***p=0.080 (Fisher’s exact test); p=0.045 (Chi square test) 
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Fig. 5. Significance of mycoplasmas in relation to prostatitis according to PCR results 
* p=0.032 (Fisher’s exact test) 
** p=0.026 (Fisher’s exact test), p=0.029 (logistic regression analysis) 
 
68 
12. Oxidative stress in chronic prostatitis patients 
 
We compared the presence and rate of oxidative stress (OxS) in inflammatory 
prostatitis patients (NIH IIIA and NIH IV categories; Fig. 2) and controls. No 
significant differences were observed when patients and controls were com-
pared for age, period of sexual abstinence and basic sperm parameters (semen 
volume, sperm concentration, total sperm count and motility). In addition to ele-
vated WBC counts, we observed an elevation of IL-6 levels in the patient group 
that confirmed inflammatoriness of the prostatitis (Table 9).  
 
 
Table 9. Clinical and basic semen parameters of the prostatitis patients and controls 
 
 Prostatitis patients 
(n=21) 
Controls (n=9) P value 
Mean ± SE Mean ± SE  
Age (years) 32.3±1.4 31.2±2.6 ns 
Period of abstinence (days) 4.08±0.41 5.11±0.87 ns 
Semen volume (ml) 3.89±0.32 4.77±0.63 ns 
Sperm concentration (million/ml) 56.47±13.73 57.11±13.95 ns 
Total sperm count (million) 213.53±48.78 234.27±44.03 ns 
A+B motility (%) 45.33±3.67 50.79±4.98 ns 
White blood cells in semen 
(million/ml) 
2.48±0.96 0.11±0.02 0.001 
IL-6 in seminal plasma (pg/ml)* 73.74±29.59 11.48±5.14 0.020 
hsCRP in blood serum (mg/L) 0.89±0.14 1.26±0.51 ns 
Prealbumin in blood serum (g/L) 0.41±0.02 0.44±0.03 ns 
ns – not significant 
* – IL-6 measurements were performed in 8 prostatitis patients and 6 controls  
We did find relevant information on various aspects of OxS (antioxidants, pro-
oxidants and oxidation products) from local samples (spermatozoa and seminal 
plasma) as well as from samples of systemic nature (urine and blood). 
 
 
 
 
12.1. Oxidative stress in spermatozoa 
 
The total antioxidative status in water environment (TAS) of spermatozoa 
decreased in inflammatory prostatitis patients compared with controls, as shown 
in Table 10. Level of TAS also exhibited a strong negative correlation with 
WBC (R=–0.64, p<0.001). At the same time, lipid peroxides (diene conjugates, 
DC) were statistically significantly increased mainly because of the damage of 
spermatozoon membrane.  
This evidence suggests that spermatozoa of the leukocytospermic men have 
increased OxS. For the interpretation of the OxS parameters in the spermatozoa 
it should be noted that the spermatozoa need low levels of ROS, especially hyd-
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rogen peroxide and superoxide radical for the capacitation (tyrosine phospho-
rylation, hyperactivation and acrosome reaction) (Aitken 1997, 2004, Rivlin et 
al., 2004). If the generation of ROS becomes elevated for any reason, sperma-
tozoa possess a limited capacity to protect themselves from OxS (Baker and 
Aitken, 2005). TAS measurement in spermatozoa has been implemented for 
purpose of comparing infertile and fertile men, without finding any difference 
(Verit et al., 2007). In the spermatozoa, the thiols seem much more important 
contributors to antioxidant defense than vitamins C and E (Lewis et al, 1997). 
 
 
12.2. Oxidative stress in seminal plasma 
 
Oxidative damage of seminal plasma lipids in the inflammatory prostatitis pa-
tients appears higher than in the healthy controls, as suggested by the higher DC 
content in the seminal plasma of leukocytospermic men (Table 10). Also, the 
level of total antioxidative activity (TAA%) showed lower values in prostatitis 
patients compared to these of healthy controls. We also observed an analogous 
but weak trend concerning total antioxidative status (TAS). Not surprisingly, 
there was also a strong negative correlation between seminal plasma measure-
ments of TAA% and DC (R= −0.54, p=0.002). Our data correspond to previous 
studies that have shown lower TAS in leukocytospermic men (Omu et al. 1999; 
Omu et al 1998. Pasqualotto et al., 2001; Agarwal et al., 2003).  
The TAS, indicating total antioxidative status in water-soluble environment 
and based on water-soluble molecules like vitamin C (Erel, 2004), revealed a 
good positive correlation with that vitamin, indeed (R=0.69, p<0.0001). The 
vitamin C levels in seminal plasma had lower values in prostatitis patients with 
severe inflammation (>1 M WBC/ml) than in control group (28.06±10.47 vs 
40.79±10.47, p=0.0002) although the whole group did not reach the level of 
statistical significance (p=0.09). It has been shown that vitamin C deficiency 
may reduce sperm characteristics and facilitate DNA damage (Ebesunun et al., 
2004, Song et al., 2006); the same applies to TAS (Koca et al., 2003). 
We observed very low concentrations of GSH in seminal plasma that cor-
respond with the earlier studies (Yeung et al., 1998; Storey et al., 1998) and 
there were no significant differences between control and patients group. 
In our study, the level of Zn in seminal plasma was lower in prostatitis pa-
tients compared to healthy controls yet not reaching the significance level. Zinc 
levels in seminal plasma have been positively associated with sperm con-
centration and motility in some studies (Fuse et al., 1999; Chia et al., 2000) but 
not in others (Lewis-Jones et al., 1996; Lin et al., 2000). Reduced zinc levels in 
seminal plasma of men with leukocytospermia or Ureaplasma urealyticum in-
fection have been reported (Omu et al. 1999; Han et al., 2003). The exact con-
centration of Zn in seminal plasma in vivo is unknown since the unbound Zn 
fraction depends on the post-ejaculatory redistribution of the ion from prostate 
to high affinity vesicular ligands (Carpino et al., 1998). 
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 12.3. Systemic oxidative stress 
 
We found differences between the inflammatory prostatitis patients and healthy 
men concerning markers showing systemic OxS, as revealed by 8-EPI in urine 
and glutathione (GSH) in red blood cells. The levels of 8-EPI in the urine of 
inflammatory prostatitis patients were significantly elevated when compared to 
healthy controls (Table 10). This marker correlated well with 8-OHdG, which 
indicates oxidative damage of DNA (R=0.45, p<0.01; Fig. 6). In addition, 8-
OHdG correlated with intraspermatozoal Fe (R=0.52, p<0.004) and Ni (R=0.48, 
p=0.008).  
Isoprostanes are prostaglandin-like substances that are produced in vivo 
independently from a cyclooxygenase (COX), primary by free radical-induced 
peroxidation of arachidonic acid (Morrow et al., 1990). They are released in 
response to cellular activation, circulate as a free form or as esters in phospho-
lipids in plasma and excreted in urine. The measurement of isoprostanes in bio-
logical fluids has prompted clinical investigations on the pathophysiological 
role of lipid peroxidation in human disease.  
Elevated production of ROS associated with DNA damage in immature 
spermatozoa seems to impair spermatogenesis (Ollero et al., 2001; Baker and 
Aitken, 2005). Elevated level of ROS may cause a release of iron from endo-
genous iron proteins such as tissue ferritin and transferrin, as well as modulate 
their expression (Niwa et al., 2003; Polla et al., 2003). Ni may affect genetic 
material directly or indirectly, via Fenton-like chemistry leading to ROS, 
causing DNA strand breaks and oxidative modifications of bases (Manini et al., 
2003). Induction of DNA single-strand breaks, DNA protein cross-links, sister 
chromatid exchanges and chromosomal aberrations has been demonstrated with 
various nickel salts (Doreswamy et al., 2004). 
In this study, we found no relation between glutathione and sperm motility 
although in a placebo-controlled double-blind infertility study it was shown that 
glutathione supplementation positively affected sperm motility (Lenzi et al., 
1993). Unlike the studies regarding NIH II (chronic bacterial) prostatitis by 
Zhou et al. (2006) and Lou et al. (2006), our results did not reveal differences in 
vitamin C levels, which could be expected to contribute to the antioxidative 
defense as well. 
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12.4. Seminal microflora in respect to oxidative stress 
 
In an agreement with our earlier studies, no sterile semen samples were found 
from patients (Table 3 in Paper IV) or controls. 119 isolates were successfully 
identified and subsequently allocated into 20 microbial groups. 32% of strains 
were identified to species levels; others were identified to genus level or to a 
broader category like coagulase-negative staphylococci (CNS). The number of 
different microorganisms in one sample ranged from 1 to 8, the total microbial 
concentrations ranged from 5x103 to 7x105 CFU/ml. Corynebacterium group G 
showed association with inflammatory prostatitis because its quantities in the 
semen samples correlated with concentration of seminal white blood cells 
(R=0.55; p=0.002). Another coryneform species, C. seminale emerged to show 
the inverse properties showing a positive correlation with intracellular TAS 
(R=0.44, p=0.02). These two microorganisms were inversely associated as well 
(R=-0.38, p=0.04). 
Elevated level of leukocytes in semen has generally been considered an indi-
cator of infection although routine cultures are rarely successful. Our previous 
studies have revealed a wide profile of microorganisms in the semen of chronic 
prostatitis patients where extended quantitative microbiological methods were 
used (Punab et al., 2003; Kermes et al., 2003; Korrovits et al., 2006). Therefore, 
we applied a similar analysis in this study. As expected, the polymicrobial 
communities were found in all prostatitis patients containing both aerobic and 
anaerobic bacteria.  
Previous investigators have performed an in vitro test where some micro-
organisms were assessed for their capability to produce ROS and damage the 
lipid membranes of spermatozoa when coincubated with WBC. As a result, 
Bacteroides ureolyticus, Staphylococcus haemolyticus and Escherischia coli 
were found to cause more damage to sperm membrane lipids than Streptococcus 
oralis and Ureaplasma urealyticum; the role of ROS was confirmed by 
measuring malondialdehyde levels (Fraczek et al., 2007). In spite of relatively 
modest proclivity for damaging sperm membrane lipids, U. urealyticum has 
been nevertheless associated with increased ROS in the semen of prostatitis 
patients (Potts et al., 2000). In a study by Shahed and Shoskes (2000), a 
connection between Gram-positive organisms in semen and isoprostane levels 
was found. However, their pioneering publication provided no details on the 
numbers and composition of species, though. 
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Table 10. Markers of oxidative stress and related metals in semen, urine and blood of 
inflammatory prostatitis patients and controls 
 
 
Prostatitis 
patients 
(n=21) 
Mean ± SE 
Controls 
(n=9) 
Mean ± SE 
P value 
 In spermatozoa: 
DC (µM) 9.80±0.98 5.02±0.47 0.001 
TAS (mmol/L) 0.08±0.01 0.19±0.02 0.001 
Zn (mg/L) 0.10±0.03 0.14±0.05 ns 
Fe (mg/L) 0.55±0.14 0.57±0.15 ns 
Ni (mg/L) 0.17±0.04 0.12±0.03 ns 
Zn/Fe ratio 0.38±0.07 0.40±0.12 ns 
In seminal plasma: 
DC (µM) 6.16±0.81 2.96±0.63 0.015 
TAA (%) 35.00±1.32 41.11±1.23 0.009 
Vitamin C (mg/L) 30.57±2.60 40.79±6.78 ns 
TAS (mmol/L) 1.56±0.04 1.69±0.11 ns 
GSH (µM) 0.92±0.11 0.85±0.28 ns 
Zn (mg/L) 72.7±53.6 101.4±28.6 ns 
Fe (mg/L) 0.10±0.01 0.27±0.17 ns 
Ni (mg/L) 0.02±0.00 0.02±0.00 ns 
Zn/Fe ratio 739.41±254.95 925.75±236.42 ns 
In urine: 
8-isoprostanes (ng/mL) 5.79±1.56 2.53±0.92 0.0001 
8-OHdG (ng/mL) 11.66±4.62 8.04±2.47 ns 
In blood: 
DC (µM) 45.90±2.28 43.17±2.56 ns 
TAS (mmol/L) 1.13±0.03 1.09±0.04 ns 
Vitamin C (mg/L) 6.85±0.60 6.26±0.90 ns 
GSH (µM) 983.43±57.22 1157.44±72.65 0.037 
GSSG (µM) 38.29±7.01 29.44±11.09 ns 
Glutathione redox ratio 0.04±0.01 0.03±0.01 ns 
Fe (µmol/L) 21.12±1.93 19.78±0.98 ns 
Ferritin (µg/L) 130.77±14.66 152.09±37.05 ns 
Transferrin receptors (mg/L) 1.59±0.07 1.62±0.11 ns 
ns – not significant 
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Fig. 6. The positive association between the levels of (A) 8-isoprostanes and 8-OHdG in 
urine; (B) Fe in spermatozoa and 8-OHdG in urine; and (C) Ni in spermatozoa and 8-
OHdG in urine. 
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GENERAL DISCUSSION 
 
In the 21st century, scientific community has paid somewhat more attention to 
prostatitis than in the past century. From the theoretical viewpoint, there have 
been no paradigm shifts but a gradual accumulation of knowledge about epide-
miology, etiology and pathogenesis. In addition to the main etiological theories 
(infectious, autoimmune and neuromuscular), other theories (urothelial, distal 
urethral web) have been developed as well (Parsons, 2007; Vega, 2002). 
 Since the etiopathogenesis of prostatitis syndrome is still largely unknown 
and thereby the evidence based treatment suggestions are very scarce, additional 
studies are urgently needed in this field. Therefore, we have taken under in-
vestigation some microorganisms that cannot be revealed or that may remain 
beyond attention during routine cultures. We also tried to clarify the role of oxi-
dative stress (OxS) as one possible pathogenesis mechanism of prostatitis. 
 
 
13. Role of coryneform bacteria in prostatitis 
 
Coryneform bacteria are Gram-positive rods. While leaving obvious exceptions 
like toxigenic C. diphtheriae aside, the mucosal Gram-positive microorganisms 
are generally considered commensals. However, Shahed et Shoskes (2000) sug-
gested that these common Gram-positive organisms could actually be associated 
with prostatitis in some men, and they even classified these organisms as indi-
cators of bacterial prostatitis (NIH II). Our current as well as previous data 
(Kermes et al., 2003) support the evidence that Gram-positive organisms may 
sometimes be associated with prostatitis but it depends on their species and 
counts. 
On one side, according to our data coryneform bacteria in general are more 
or less equally prevalent among patients and controls. On the other side, their 
species composition and total counts can be individually variable and signifi-
cantly health-associated. The latter was shown by differences between prosta-
titis patients and controls both at qualitative (list of species) and quantitative 
(predominant species) level. Hence, our data supports the idea that coryneform 
bacteria are not uniform but a diverse group of organisms containing both 
commensals and pathogens, and some species are probably more associated 
with prostatitis than the others. However, these microorganisms do not probably 
act as separate pathogens but they may rather fit into multibacterial community 
existing in male genital tract in case of prostatitis. The large number of unusual 
species in high quantities might colonize prostatitis patients not as much be-
cause of particular virulence of these species but rather because of reduced im-
munity of the patients. The situation can be explained better by paradigm of 
dysbacteriosis – a disturbance of balance between immune system and normal 
microbiota leads to an abnormal immune response combined with respective 
aberrations of normal microbiota. Alternatively, if only one or two endogenous 
opportunists from the pool of many potential agents occupy the niches pre-
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viously protected by functional immune system, then opportunistic infection 
would be a better description of the prostatitis. Tentatively, the following three 
examples could eventually lead to imbalance of microbiota: urinary reflux com-
bined with an impaired urothelium negates desquamation, facilitates invasion 
and irritates the surrounding tissues; neuromuscular spasm could cause an accu-
mulation of ROS and a depletion of antioxidants, which could lead to dete-
rioration of the immune barriers of the prostate; calcifications in the prostate 
provide an opportunity for a foreign body biofilm infection for the occasional 
bacteria that have incidentally migrated into the prostate. In addition, this could 
explain focal and recurrent nature of infections, as antibacterial treatment can 
probably suppress but not eradicate a biofilm infection from the prostate. 
Therefore preventive strategies, probiotics and immunomodulation might be 
more helpful. The spectrum and pathogenecity of coryneforms could be conclu-
sively demonstrated by a high-quality metagenomic biopsy study. The problems 
with biopsies include difficulties to avoid contamination (at least in a living 
patient), and difficulties in recruiting a control group. 
 
 
14. Role of mycoplasmas in prostatitis 
 
Mycoplasmas are the smallest free-living bacteria that cannot be cultured by 
routine methods. Therefore, our current knowledge about them is scarce. These 
organisms have been associated with male genital tract infections during last 
decades. Moreover, their classification has been changed over time and there-
fore comparison of published data is complicated. To date, Mycoplasma genita-
lium is considered a more likely causative agent of urethritis than ureaplasmas. 
Since prostatitis may be a consequence of an untreated sexually transmitted 
disease, the role of mycoplasmas needs elucidation in the context of prostatitis 
as well. 
By our data, mycoplasmas in general are more common among the patients 
than controls. Our study also confirmed that the lack of discrimination between 
Ureaplasma urealyticum and Ureaplasma parvum has been an important 
shortcoming in many studies. Before the tests that are more specific became 
available, Ureaplasma urealyticum was considered as prostatitis pathogen by 
Ohkawa et al. (1993) and Skerk et al. (2002) although not by Berger et al. 
(1989). According to our study, it was actually Ureaplasma parvum that as-
sociated with prostatitis, not Ureaplasma urealyticum. Hence, this former lack 
of discrimination between two ureaplasmas probably presented U. urealyticum 
to scientific community as more pathogenic than it actually is. Although Myco-
plasma genitalium was found in our study from few subjects only, all of these 
men had category IIIa prostatitis that supports the possible association of this 
species with prostatitis.  
In the light of current evidence, the associations between prostatitis and 
mycoplasmas could be explained by the concept of imbalanced microbial com-
munities like in case of coryneform bacteria. Alternatively, the route of sexual 
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transmission might at least partially explain the recurrence of a mycoplasma 
infection. Without regard to prostatitis symptoms, the adverse effect of some 
mycoplasmas on the spermatozoa justify using antibacterial agents directed 
against these microorganisms, anyway. One reason for this is that U. urealy-
ticum is detrimental for motility of the spermatozoa (Zeighami et al., 2009). As 
is the case with coryneforms, the pathogenicity of different mycoplasma species 
could be conclusively demonstrated by a high-quality metagenomic prostate 
biopsy study. 
 
 
15. Role of oxidative stress in prostatitis 
 
Although definitions of OxS may vary, usually it means that harm to biological 
systems is being facilitated by free radical oxidants. While infectious etiology 
has been suspected for several decades, OxS has not been that relevant so far. 
Oxidative stress may be either beneficial (eustress) or harmful (distress). In one 
hand, breathing is an oxidative process, and even spermatozoa require some 
ROS in order to become functional (Aitken et al., 2007). On the other hand, 
excessive production of free radicals is detrimental for the organism. Studies 
have suggested causes of OxS: neural sensitization (Schwartz et al., 2008), 
autoimmunity (Motrich et al., 2008), prostate infection and leukocytospermia 
(Elkahwaji et al., 2008; Shahed et Shoskes, 2001; Saleh et al., 2002), smoking 
(Kiziler et al., 2007), diet (Holt et al., 2009) and reduced physical activity 
(Ghosh et al., 2009). Earlier experiences that showed importance of oxidative 
mechanisms in various diseases gave us incentive to include an analysis of OxS 
in our prostatitis study.  
We have performed a many-sided complex study by measuring markers 
of OxS (antioxidants, pro-oxidants and oxidation products) from levels of both 
local (spermatozoa, seminal plasma) and systemic (blood and urine). Our most 
important conclusion is that the patients have OxS not only on the level of 
semen and spermatozoa but on the systemic level as well, which could be a risk 
factor for many other diseases. Systemic OxS was demonstrated by increased 8-
isoprostane (8-EPI) concentrations in urine that was in good correlation with a 
marker of DNA damage. Since 8-EPI are markers of lipid peroxidation in 
vascular diseases, hence prostatitis and some cardiovascular diseases share a 
pathogenetic component that could explain associations between these diseases. 
In fact, isoprostanes (and even PGF2α) can be produced by free radical mecha-
nisms (Proudfoot et al., 1995; Roberts et al., 2004; Yin et al., 2007). As con-
cerns semen, seminal plasma is usually well endowed with an array of antioxi-
dant defenses to protect spermatozoa against oxidants. Antioxidants in the semi-
nal plasma usually compensate for the deficiency of cellular enzymes in the 
spermatozoa. The high-grade OxS will develop in the case of genitourinary in-
fection or inflammation because of reduced antioxidant levels and/or increased 
production of free radicals. According to our data, the bodies of prostatitis pa-
tients have both more oxidation products and less antioxidants. We found less 
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antioxidants even in the spermatozoa, where the absolute quantities of anti-
oxidants are very low both in physiological as well as pathogenic conditions. 
Oxidative damage in spermatozoa correlated with major pro-oxidants iron and 
nickel measured in the same site. The antioxidant system present in seminal 
plasma in conditions of natural reproduction must exert its action over a relati-
vely short period, ranging from ejaculation to sperm transfer into the female 
tract, whereas the antioxidant system present in membranes of the spermatozoa 
must maintain their activity over prolonged periods, covering also duration of 
spermatozoid storage in the female reproductive organs.  
From the microbiological point of view, local OxS may be useful, because it 
has been observed that hydrogen peroxide (product of SOD), even in low 
concentrations (0.1 mM) decreases abilities of uropathogenic E. coli to adhere 
and resist blood serum and phagocytosis (Hegde et al., 2008). On the other 
hand, Fraczek et al. (2007) have associated the harmful effect of bacteria upon 
spermatozoa with OxS, and demonstrated that this effect is species-specific: 
Escherichia coli, Staphylococcus haemolyticus and Bacteroides ureolyticus 
caused more lipid peroxidation in spermatozoa than Streptococcus oralis and 
Ureaplasma urealyticum did, as measured by malondialdehyde levels. Shahed 
and Shoskes (2000, 2001) have shown that OxS in semen is linked to Gram-
positive bacteria. Our microbiological results from OxS study were rather 
quirky in nature. Corynebacterium group G associated with inflammation while 
C. seminale associated with better antioxidative status of spermatozoa and dis-
played a tendency towards mutual exclusion with Corynebacterium group G. 
The current evidence does not allow determining causal relationships between 
microorganisms and OxS. It would be necessary to determine microorganisms’ 
ROS production, ROS tolerance and capability to inhibit each other’s growth. 
Hence, our data may indicate that microbiota might be relevant for sperm 
quality. 
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16. Possible vicious circles  
in the pathogenesis of prostatitis 
 
The current scientific results enable to construct possible vicious circle mecha-
nisms for prostatitis. Oxidative stress may be one of the key links in a vicious 
circle. 
One possible vicious circle would tie together urinary reflux theory, urothe-
lium dysfunction theory, calcifications, infection and oxidative stress. If bacteria 
in urine encounter prostatic calcifications, then the consequence is a biofilm in-
fection and immune activation. If these bacteria irritate dysfunctional 
urothelium, then the result is irritation and immune activation. Local immune 
activation results in local oxidative stress that contributes via circulation to 
systemic oxidative stress. Systemic oxidative stress results in urinary excretion 
of isoprostanes and PGF2α, which by irritating the prostate region locally close a 
positive feedback loop (It has been shown that PGF2α causes urethral 
contractions in humans while 8-epi-PGF2α-epi has exhibited same traits in 
animal study (Tarcan et al. 2000, Andersson et Persson, 1977)). Since smoking 
raises 8-epi-PGF2α levels, then we would have an example mechanism how 
smoking could contribute to prostatitis (Patrono et Fitzgerald 1997). Urethral 
contractions might cause pain in cases of both calcifications and impaired 
urothelium. This suggests a possible vicious circle (Fig. 7).  
Another vicious circle involves a prostatic injury that induces oxidative 
stress in central nervous system, which in its own turn becomes as if reci-
procally sensitized to pain (Schwartz et al., 2008; Lee et al., 2007). Animal 
study from Schwartz et al., (2008) suggests that ROS generation in spinal cord 
due to peripheral injury takes place in mitochondria, and that is precisely where 
Mn-SOD is usually located. Although SOD dismutates superoxide into hydro-
gen peroxide that is itself capable of causing pain through TRPV1 receptor 
(Keeble et al., 2009), an observation of SOD levels in spinal cord suggests that 
SOD activity actually protects from the pain (Schwartz et al., 2009). Perhaps 
that is because superoxide may react with nitric oxide to form peroxynitrite that 
seems a truly harmful molecule as it can escalate oxidative stress and exacerbate 
pain as nitration of SOD and opiate receptors leaves superoxide levels and 
nociception, respectively, unchecked (Salvemini et Neumann, 2009). Nevethe-
less, it must be repeated again that the mere activity of ROS, in physiological 
concentrations, controlled and properly compartmentalized, is a crucial part of 
our healthy physiology, which probably functions better without unnecessary 
interference (Gomez-Cabrera et al., 2005; Bjelakovic et al., 2008). 
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Fig. 7. Possible vicious circle in case of chronic prostatitis 
  
 
If bacteria persist in the prostate, then it would be interesting to know why. 
Blaser and Kirchner (2008) have analyzed the dynamics of bacterial persistence 
by the use of game theory (pioneered by Neumann et Morgenstern, 1944). Their 
formula explains the mechanisms behind bacterial persistence in hosts: 
 
R0 = BN/(α+b+ν), 
 
where R0 is transmission potential of the microorganism, BN is the transmission 
rate depending on population size N, α is the mortality rate of hosts due to 
microorganism’s virulence, b is mortality of hosts not due to microorganisms 
(lifespan), ν is the rate by which host’s immune system eradicates the bacteria 
from the host. If all variables were independent, then a negative α (symbiosis) 
would be favorable but if virulence grants better transmissibility, then some 
virulence would be favorable, instead, especially if there are plenty of inter-
acting hosts that create many opportunities for transmission. Neither urogenital 
mycoplasmas nor coryneforms are highly virulent but the virulence might 
increase over time if there is an increase in virulence-dependent transmission 
opportunities and if unhealthy lifestyle contributes to prostate’s immune 
systems inability to keep these unwanted guests at bay. While risk factors of 
prostatitis have been discussed in detail in previous chapters, it may be of 
interest that the transmission opportunities (carriage) of nasal coryneforms were 
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reduced in persons who had high titers of antibodies against diphtheria toxoid 
(Bergamini et al., 2002). 
According to Shoskes et al. (2007), as if two types of prostatitis patients 
existed: one group had infection, inflammation and prostatic stones but no pel-
vic spasms, while the others had pelvic muscle sensitization. This makes it 
plausible to believe that the prostatitis begins either by infection or by sensiti-
zation. The possibilities of propagation are numerous: autoantibody-driven 
inflammation, lifestyle choices, ROS-mediated positive feedback in urinary 
tract or nervous system, mild biofilm infection associated with prostatic calculi, 
etc. Currently, there are many competing theories that ought not be prematurely 
welcomed as ‘final’, or discarded altogether. 
While hardly a confounder, it is difficult to estimate whether oxidative stress 
is an initiator or a propagator of CPPS. Be it one way or the other, or both of 
them, it seems that oxidative stress is a central pathogenetic mechanism of 
prostatitis.  
 
 
17. Some considerations of prostatitis treatment 
 
Considering that CP/CPPS is a chronic pain syndrome that is difficult to treat, it 
is no wonder that both patients and doctors may be quite frustrated with 
prostatitis (Nickel, 2000). In fact, initial treatment of prostatitis is quite simple 
and straightforward – prescription of fluoroquinolones (Nickel 2002; Murphy et 
al., 2009). As explained by Wood et al., (2007) the doctors have social respon-
sibility and must deal with immediate needs of the patients. Such urgent needs, 
or perception thereof, may get priority over long-term needs of both patient and 
doctor. Considering that doctors may have to comply with patients’ expecta-
tions quickly as well as justify their treatment decisions later, it seems possible 
that doctors make decision pertaining treatment before they see the results of 
microbiological analysis. According to Liu et al. (2008) as well as Ku et al. 
(2005), culture test results actually did not influence treatment decisions – it 
seemed that ordering culture test was just a tradition or a means to rationalize 
previously made treatment decisions. Majority of physicians are willing to 
prescribe a second course of fluoroquinolones even after they have failed the 
initial one (Ku et al., 2005). It has been reported that there is a sevenfold 
overuse of fluoroquinolones (Taylor et al. 2008). The arguments in favor of 
common fluoroquinolones include low price, safety (Meropol et al., 2008) good 
penetrability into prostate (Nickel, 2002), success stories of treatment (Jeong et 
al., 2003), and belief into infectious etiology that is not based on microbiolo-
gical evidence. The arguments against using fluoroquinolones consist of 
controlled studies (Nickel et al., 2003; Alexander et al. 2004). This discrepancy 
in the treatment of prostatitis is of utmost importance concerning health, econo-
my, and research. Therefore, more evidence-based suggestions for treatment are 
needed.  
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If it is assumed that the symptoms of prostatitis are a consequence of in-
fection, then one must identify (1) causative agents or at least likely causes of 
infection; (2) means that can eliminate the causes or at least ameliorate the con-
sequences (universally or case-by-case). There is a reason to believe that in ad-
dition to acknowledged urinary tract pathogens (like E. coli and enterococci), 
prostatitis may be associated with some other bacteria that can be eliminated 
with antibiotics. Certain coryneform bacteria may be one of the candidates. 
Their possible association with prostatitis has been proposed in some previous 
studies (Tanner et al., 1999; Domingue 1998) as well as our present study. 
Since half of the prostatitis-associated Corynebacterium group G is not suscep-
tible to norfloxacin, it raises questions about the feasibility of treating prostatitis 
with fluoroquinolones. Instead, traditional and cheap antibiotics like penicillin 
and TMP/SMX have quite good activity against the urogenital coryneform 
strains in vitro. Penicillin susceptibility is the common denominator of Coryne-
bacterium group G, as well as β-hemolytic streptococci and peptostreptococci, 
the latter being associated with prostatitis by our earlier research (Kermes et al., 
2003). Therefore, β-lactams might have potential, especially those, which penet-
rate into the prostate. For examples, ampicillin penetrates into the prostate with 
a serum-tissue ratio of 2:1 (Jeppesen and Frimodt-Møller, 1984), and 
piperacillin-tazobactam is superior to ciprofloxacin in preventing infections 
after transrectal prostate biopsy (Cormio et al., 2002).  
Another group of microorganisms that shows association with prostatitis, 
according to our study, is that of mycoplasmas. Only a short list of antibiotics 
can be used for the eradication of these facultatively intracellular bacteria: 
macrolides, tetracyclines and fluoroquinolones. Use of these antibiotics is cer-
tainly justified if either M. genitalium or U. parvum is found from a prostatitis 
patient. Tetracycline is preferable against U. parvum while azithromycin is 
preferable against M. genitalium (Biernat-Sudolska et al., 2009; Mena et al., 
2009).  
At the same time, there are several other factors to consider, in addition to 
antibiogram of supposed causative agent(s). Damage of beneficial micro-
organisms should be avoided to prevent overgrowth of adverse communities. 
From that aspect, antibiotics of narrow spectrum are preferred. In addition, in 
vivo treatment results may differ from in vitro susceptibility results of suspected 
bacteria since the bacteria might persist in calculi, biofilms or urinary epithelial 
cells. Therefore, targeting the patient or removing the habitat of bacteria – sur-
gical correction of anatomical deviations and riddance of prostatic stones – may 
be a more reasonable strategy in (Shoskes et al. 2007; Domingue et Hellstrom 
1998; Vega 2000). Interactions between host and microbiota might be improved 
by immunomodulation and dietary or supplementary antioxidants. The latter 
suggestion is in accordance with our study results, which indicated that both 
local as well as generalized oxidative stress is a major participant in the 
pathogenesis of inflammatory prostatitis. 
If restoration of prostatitis-associated fertility is aimed by means of anti-
bacterial treatment, then the association between C. seminale and improved 
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antioxidant defenses of spermatozoa combined with inherent tetracycline resis-
tance of that species might influence antibiotic choice in treating men who are 
colonized with C. seminale. Another beneficial facet of tetracyclines is that 
these target Ureaplasma urealyticum, and Chlamydia trachomatis that deterio-
rate the quality of semen (Zeighami et al., 2009; Mazzoli et al., 2009). 
Older tetracyclines, penicillins and fluoroquinolones are all quite inexpen-
sive and safe. Long-term consumption of doxycycline, ciprofloxacin and amo-
xicillin causes very few hospitalization-requiring severe adverse effects (respec-
tively up to 0,9 and 1,2 and 5,2 cases per 100 000 days of treating a patient) 
according to Meropol et al. (2008). There is an avenue for limiting healthcare 
costs by not extending the subsidies for the consumption of newer fluoro-
quinolones until their worth in prostatitis treatment is backed up by evidence. 
Since the etiopathogenesis of prostatitis is still largely unknown and since 
antibiotic are not always successful, a long list of other treatment modes is in 
use as well. As concerns evidence of controlled studies, α-blockers have been 
superior to placebo in five of six studies (Cheah et al., 2003; Mehik et al., 2003; 
Sivkov et al., 2005; Nickel et al., 2004; Alexander et al, 2004; Evliyaoğlu et 
Burgut, 2002). Two of two controlled studies (Elist et al., 2006, Wagenlehner et 
al., 2009) agree with pollen extracts being useful. There is currently no 
evidence whether and how these treatments affect interactions between the host 
and urogenital microbiota, but it would be both theoretically and practically 
interesting to see whether modifying the host responses could correct the host-
bacteria relationships in case of inflammatory prostatitis, too. 
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CONCLUSIONS 
 
Our study updates the current knowledge of the role of seminal microbiota and 
oxidative stress in the etiopathogenesis of chronic inflammatory (categories 
NIH III and IV) prostatitis. 
1)  Polymicrobial communities are present in the semen of all prostatitis patients 
containing both aerobic and anaerobic bacteria. Coryneform bacteria form a 
significant proportion of this microbiota. Localization study suggests that their 
source in prostatitis patients is not the normal-microflora-containing urethra. 
In addition, significantly longer list of coryneforms can be found in high 
concentration in inflammatory prostatitis patients than in controls. Coryne-
bacterium group G is associated with inflammatory prostatitis in case of se-
vere leukocytospermia, which suggests that this species might participate in 
the etiopathogenesis of prostatitis as an initiator of inflammation. 
2)  Penicillins and TMP/SMX express the highest in vitro antimicrobial activity 
against seminal coryneform bacteria that are frequently non-susceptible to 
several other antimicrobials. MLSb resistance pattern is common among 
seminal coryneforms. Corynebacterium group G strains frequently resist 
norfloxacin, nitrofurantoin, clindamycin, and erythromycin. Susceptibility 
data are useful for empiric therapy of prostatitis patients and clinical drug 
research. 
3)  Our findings suggest that some mycoplasma species, U. parvum and M. ge-
nitalium participate in the etiology of chronic prostatitis. Distinction between 
Ureaplasma urealyticum and M. parvum is certainly necessary since only 
the latter has a tendency of being more prevalent among prostatitis patients 
than controls. Mycoplasma genitalium may be linked with NIH IIIa prosta-
titis. 
4)  Inflammatory prostatitis patients have both local and systemic oxidative 
stress, as evident in its various forms (reduced antioxidant levels and in-
creased levels of pro-oxidants and oxidation products). Local oxidative 
stress comprises increased oxidative stress in both seminal plasma and 
spermatozoa. As the sperm cells are highly susceptible to oxidative injury, 
this mechanism may be associated with prostatitis-related decrease of ferti-
lity. In addition to local shifts, decreased GSH in erythrocytes and increased 
8-EPI in urine (in association with DNA oxidation) are signs of systemic 
oxidative stress. As 8-EPI can cause smooth muscle contraction in the uri-
nary bladder, this oxidative stress byproduct may therefore facilitate the uri-
nary tract dysfunction in prostatitis patients and it may contribute to the pro-
pagation of a vicious circle that upkeeps the prostatitis symptom complex. 
Moreover, systemic oxidative stress means that inflammatory prostatitis 
patients may have increased risk for other diseases. 
5)  The association between Corynebacterium seminale and better antioxidant 
status of spermatozoa as well that of between Corynebacterium group G and 
severe inflammation suggests that these bacteria deserve further attention 
because of their therapeutic or diagnostic potential, respectively. 
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SUMMARY IN ESTONIAN 
 
Kroonilise prostatiidi etiopatogeneetilisi aspekte: 
mükoplasmad, korüneformsed bakterid ja  
oksüdatiivne stress 
 
Sissejuhatus 
 
Eesnäärmepõletik ehk prostatiit on lai mõiste, mis hõlmab haiguste gruppi, mil-
lest osa on ebaselge tekkepõhjusega. National Institutes of Health (NIH) klassi-
fikatsioonis on kaks selge etioloogiaga prostatiiti – äge bakteriaalne prostatiit 
(NIH I) ja krooniline bakteriaalne prostatiit (NIH II) (NIH Chronic Prostatitis 
workshop in Bethesda, MD, 1995). Ülejäänud prostatiidi vormid (NIH III ja 
NIH IV) on oluliselt sagedasemad, kuid samas ebaselge etioloogiaga. NIH III 
kategooria ehk kroonilise prostatiidi / kroonilise väikevaagnavalu sündroom 
diagnoositakse siis, kui mehel on kolme kuu jooksul olnud vaagnapiirkonna 
valu ja muid kroonilise prostatiidi sümptomeid, kuid patogeene ei leita. Põh-
justeks peetakse peamiselt infektsiooni, autoimmuunsust või närvi-lihassüs-
teemi häiret. Prostatiidi olulisus tuleneb eelkõige massilisest levimusest – ligi-
kaudu kümnendik meestest kannatab kroonilise prostatiidi sümptomite all (Me-
hik et al., 2000; Bartoletti et al., 2007; Rizzo et al., 2003; Ejike et Ezeanyika, 
2008; Clemens et al., 2007; Marszalek et al., 2007; Nickel 2005). Samal ajal on 
haiguse kulg sageli krooniline ning elukvaliteedi langust prostatiidi ja müokardi 
infarkti puhul peetakse võrreldavateks (Tripp et al. 2004). NIH IV kategooria 
ehk asümptomaatiline põletikuline prostatiit on sündroom, mis sageli avasta-
takse juhuslikult muude protseduuride käigus (viljatuse ja vähi diagnostika). 
Sümptomite puudumise tõttu on seda prostatiidivormi suhteliselt vähe uuritud, 
kuid on täheldatud tema negatiivset mõju viljakusele (Korrovits et al., 2008). 
Kuna teadmised NIH III ja NIH IV kategooria prostatiitide tekkepõhjuste ja -
mehhanismide kohta on puudulikud, on ka vahendid diagnoosimiseks ja ravi-
miseks kasinad, mis tingib vajaduse täiendavate uuringute järele. Üheks käes-
oleva töö uurimisvaldkonnaks olid mükoplasmad, mille olemasolu rutiinse pros-
tatiidi diagnostika raames ei määrata, kuigi neid seostatakse järejst enam uretrii-
diga. Samuti uurisime korünebaktereid, mille etioloogilist rolli prostatiidi korral 
on varem kahtlustatud (Tanner et al., 1999), aga rutiinse analüüsi käigus jäävad 
nad enamasti tähelepanu alt välja. Kompleksuuringu käigus selgitati prostatiidi 
patogeneesi ühe võtmelüli, oksüdatiivse stressi seost mikrofloora koostise, 
mikroelementide ja sperma baasparameetritega. Käesoleva dissertatsiooni 
raames teostatud uurimused teostati TÜ Mikrobioloogia Instituudi, TÜ Bio-
keemia Instituudi ja SA TÜK Androloogiakeskuse koostööna. 
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Uurimuse eesmärgid 
 
Uuringu eesmärgiks oli saada uusi teadmisi prostatiidi etiopatogeneesi kohta. 
Selleks pöörasime põhitähelepanu mükoplasmadele ja korünebakteritele kui 
võimalikele etioloogilistele faktoritele ja oksüdatiivsele stressile kui võimali-
kule patogeneesimehhanismile. 
 
Kitsamad ülesanded olid järgmised: 
1) Võrrelda korünebakterite levimust ja liigilist koostist prostatiidiga patsien-
tidel ja tervetel. 
2)  Selgitada spermast isoleeritud korünebakterite antibiootikumtundlikkus. 
3)  Võrrelda kahe erineva meetodiga mükoplasmade levimust ja liigilist koostist 
prostatiidiga patsientidel ja tervetel. 
4)  Määrata kroonilise prostatiidiga patsientide organismis oksüdatiivse stressi 
erinevaid aspekte (antioksüdandid, pro-oksüdandid ja oksüdatsiooniprodu-
kid) nii lokaalselt (mõõdetuna spermaplasmast ja spermirakkude seest) kui 
ka süsteemselt (mõõdetuna uriinist ja verest). 
5)  Leida võimalikud seosed meessuguteede mikrofloora ja oksüdatiivse stressi 
ning põletikunäitajate vahel. 
 
 
Materjalid ja meetodid 
 
Korüneformsete bakterite uuringugruppi kuulus 109 meest (59 tervet ja 50 põ-
letikulise prostatiidiga patsienti). Põletiku olemasolu hinnati leukotsütospermia 
alusel – tugev (>106 WBC/ml; N=18) või mõõdukas (2x105 ... 106 WBC/ml; 
N=32). Vastavalt sümptomite olemasolule diagnoositi kas NIH IIIA (N=20) või 
NIH IV (N=30) kategooria prostatiiti. Patsientide keskmine vanus oli 28,5 
aastat, kontrollgrupis osalejate keskmine vanus oli 20,0 aastat. Korüneformide 
uuringust osa võtnud 30 meest (21 haiget ja 9 tervet) osalesid ühtlasi oksüda-
tiivse stressi uuringus. Kõikidele patsientidele tehti sperma baasuuring vastavalt 
WHO juhendile (WHO, 1999). Patsientide spermast ning esmasuriinist tehti ühe 
tunni jooksul kvantitatiivsed aeroobsed, mikroaerofiilsed ja anaeroobsed 
algülvid nn „nelja nurga” meetodil järgmistele söötmetele: veriagar, šokolaad-
agar, MRS agar, Gardnerella vaginalis’e agar, Wilkins-Chalgren agar, Wilkins-
Chalgren GN agar. Korüneformsed bakterid samastati Gram’i värvumuse, kata-
laasitesti, MUG-lisandiga söötme (Oxoid) ning API Coryne (BioMérieux) abil. 
Nende antibiootikumtundlikkust testiti kaheksa antibiootikumi (tetratsükliin, 
TMP/SMX, penitsilliin, ampitsilliin-sulbaktaam, norfloksatsiin, nitrofurantoiin, 
erütromütsiin, klindamütsiin) suhtes E-test meetodil (AB Biodisk).  
Mükoplasmade uuringus osales 161 meest (38 NIH IIIA, 59 NIH IIIB, 24 
NIH IV ja 40 kontroll-uuritavat). Leukotsütospermiana käsitleti WBC kontsent-
ratsiooni üle 2x105 WBC/ml. Patsientide vanus oli 22...50 (keskmiselt 34,2) 
aastat, kontrollide vanus 21…36 (keskmiselt 28,7) aastat. Kõikide meeste sper-
mast määrati Mycoplasma IST süsteemiga (BioMérieux) Mycoplasma hominis 
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ja Ureaplasma sp. Kuuskümmend proovi analüüsiti täiendavalt PCR meetodi 
abil M. genitalium, U. parvum ja U. urealyticum esinemise suhtes. DNA eralda-
miseks oli kasutusel High Pure PCR Template Preparation Kit (Roche Bio-
chemicals), praimerid ja Taq polümeraas pärinesid firmalt Fermentas. M. geni-
talium avastati praimeritega Pa1 ja MgPa3, U. parvum avastati praimeritega 
UMS-125 ja UMA-226, U. urealyticum avastati praimeritega P6 ja U8. PCR 
produktid eraldati elektroforeesi abil 2% agaroosgeelil ning visualiseeriti etiidi-
umbromiidi ja UV-kiirguse abil. 
Oksüdatiivse stressi uuringus osales 21 prostatiidiga patsienti ning 9 
kontroll-uuritavat, keskmised vanused olid vastavalt 32,3 ja 31,2 aastat. Uuri-
tavatel määrati nii oksüdatiivse stressi kui antioksüdantse kaitse näitajaid sper-
mides, spermaplasmas, veres ja uriinis. Spermide ja spermaplasma eraldamine 
toimus tsentrifuugimisel. Spermide lahutamine põletikurakkudest teostati ast-
melise Percoll gradient-tsentrifuugimise teel (30%, 50%, 70% ja 90% SIP), see-
järel määrati nende puhtuseaste ja kontsentratsioon Neubaueri hemotsütomeetri 
abil, lahjendati kontsentratsioonile 106 spermi/ml, külmutati vedelas lämmas-
tikus ning purustati pehmel meetodil (vahelduv kiire külmutamine ja sulata-
mine). Spermaproove hoiti transpordi ja tsentrifuugimise ajal jääl või +2°C 
juures. 
Uuringutes osalemine oli vabatahtlik, kõik uuringud said Tartu Ülikooli 
Inimuuringute Eetika Komitee nõusoleku. 
 
 
Tulemused ja järeldused 
 
1) Prostatiidi-patsientide spermas esinevad polümikroobsed kooslused, mis 
sisaldavad lisaks aeroobsetele ka rohkesti anaeroobseid baktereid. Korüne-
formsed bakterid moodustavad nendes kooslustes märkimisväärse osa. 
Lokalisatsiooniuuringu põhjal pärinevad prostatiidi-patsientide spermas 
leiduvad korünebakterid ülemistest suguteedest, mitte ureetrast, millest 
pärineb normaalne mikrofloora. Lisaks sellele võib patsientidelt võrreldes 
kontrolluuritavatega leida oluliselt rohkem korüneformseid liike, mis esine-
vad kõrges kontsentratsioonis. Kuigi Corynebacterium seminale on kõige 
sagedamini esinev korüneformne bakter meessuguteedes, esineb Coryne-
bacterium grupp G märksa sagedamini tugeva leukotsütospermiaga prosta-
tiidipatsientidel kui kontrollidel, mis võib viidata, et viimane osaleb prosta-
tiidi etiopatogeneesis häirunud mikrobioodi ühe komponendina.  
2) Penitsilliinid ja TMP/SMX on parimad in vitro inhibiitorid sperma korüne-
bakteritele, samas kui need bakterid on sageli vähetundlikud mitmetele teis-
tele antibiootikumidele. MLSb resistentsus on sperma korüneformide seas 
levinud. Prostatiidiga seotud Corynebacterium grupp G on resistentne mit-
metele antibiootikumidele, mida kasutatakse prostatiidi raviks, sealhulgas on 
see liik sageli resistentne nitrofurantoiini, klindamütsiini, norfloksatsiini ja 
erütromütsiini vastu. Prostatiidi polümikroobse olemuse ning sagedase 
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empiirilise ravi tõttu on potentsiaalsete etioloogiliste faktorite antibiootikum-
tundlikkuse andmed ravi valikul olulised.  
3) Meie andmed viitavad võimalusele, et mõned mükoplasmade liigid võivad 
olla prostatiidi tekkega seotud. Ureaplasma liikide (U. urealyticum ja U. par-
vum) eristamine on oluline, kuna ainult viimane esineb prostatiidiga patsien-
tidel sagedamini kui kontroll-uuritavatel. Mycoplasma genitalium võib olla 
seotud NIH IIIA prostatiidiga, kuna teda leiti ainult selle kategooria patsien-
tidel. 
4) Põletikulise prostatiidiga patsientidel esineb oksüdatiivne stress nii lokaalselt 
(rakusiseselt spermides ja rakuväliselt spermaplasmas) kui ka süsteemselt 
(veres ja uriinis). Lokaalne oksüdatiivne stress seisneb ühelt poolt oksüda-
tiivse kaitsevõime vähenemises ning teiselt poolt oksüdatsiooniproduktide ja 
pro-oksüdantidehulga suurenemises (TAS?, TAA?, DC? ja Fe?). Kuna 
spermid on väga tundlikud oksükahjustustele, võib see mehhanism olla 
aluseks prostatiidiga kaasnevale viljatusele. Lisaks lokaalsetele muutustele 
eksisteerib märkimisväärne süsteemne oksüdatiivne stress, mida näitab 8-
isoprostaanide sisalduse tõus uriinis ja selle korreleerumine DNA kahjustuse 
indikaatoriga (8-OHdG). Kuna uriinis leiduvad 8-isoprostaanid on suutelised 
tekitama põie kontraktsioone ja põletiku ägenemist, siis patsientide kuse-
teede talitluse häired ning patogeneesiahela muutumine suletud ringiks võib 
olla seotud just 8-isoprostaanidega. Üldisemas plaanis võib süsteemne oksü-
datiivne stress olla paljude haiguste riskifaktoriks. 
5) Corynebacterium seminale seos spermide parema antioksüdantse kaitsega 
ning Corynebacterium grupp G seos põletikuga viitab vajadusele pöörata 
nendele bakteritele rohkem tähelepanu nende diagnostilise või terapeutilise 
potentsiaali tõttu. 
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